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ABSTRACT OF THE DISSERTATION
REGULATION OF BONE MARROW STEM CELLS THROUGH
OSCILLATORY SHEAR STRESSES - A HEART VALVE TISSUE
ENGINEERING PERSPECTIVE
by
Sasmita Rath
Florida International University, 2015
Miami, Florida
Professor Sharan Ramaswamy, Major Professor
Heart valve disease occurs in adults as well as in pediatric population due to
age-related changes, rheumatic fever, infection or congenital condition. Current
treatment options are limited to mechanical heart valve (MHV) or bio-prosthetic
heart valve (BHV) replacements. Lifelong anti-coagulant medication in case of MHV
and calcification, durability in case of BHV are major setbacks for both treatments.
Lack of somatic growth of these implants require multiple surgical interventions in
case of pediatric patients. Advent of stem cell research and regenerative therapy
propose an alternative and potential tissue engineered heart valves (TEHV) treat-
ment approach to treat this life threatening condition. TEHV has the potential
to promote tissue growth by replacing and regenerating a functional native valve.
Hemodynamics plays a crucial role in heart valve tissue formation and sustained
performance. The focus of this study is to understand the role of physiological
shear stress and flexure effects on de novo HV tissue formation as well as resulting
gene and protein expression. A bioreactor system was used to generate physiolog-
ical shear stress and cyclic flexure. Human bone marrow mesenchymal stem cell
derived tissue constructs were exposed to native valve-like physiological condition-
ing. Responses of these tissue constructs to the valve-relevant stress states along
vii
with gene and protein expression were investigated after 22 days of tissue culture.
We conclude that the combination of steady flow and cyclic flexure helps support
engineered tissue formation as previously observed, by the co-existence of both OSS
and appreciable shear stress magnitudes, and potentially augment valvular gene and
protein expression when both parameters are in the physiological range.
viii
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CHAPTER 1
Introduction
1.1 Problem Statement
Children born with critical congenital heart valve disease require surgical in-
tervention as it is usually a life threatening condition.Statistical reports show that
8 out of 1000 live births in USA alone [1],present with anomalies of the heart, and
commonly the valve is one of the organs affected. More than five million Americans
are diagnosed with heart valve disease each year [2]. Approximately 90,000 valve
substitutes are now implanted in USA and 280,000 worldwide each year; half of
which are mechanical heart valves (MHV) and half are bioprosthetic heart valves
(BHV) [1], [3], [4].
While mechanical and tissue valves offer a promising option, their inability to
permit somatic growth after implantation remains a major drawback. In case of
MHV, patients require life-long anticoagulant for survival [5]; some patients, how-
ever, do not tolerate the noise these valves may make after implant. Alternatively,
BHV do not require anticoagulants; but durability, calcification and immunological
rejections are the major setbacks [6]. Regardless of the two valve prosthetics are
suitable for pediatric patients because of their inability to grow with the patient. As
a result, multiple surgical interventions are required to maintain the patients grow-
ing need. Therefore, for pediatric patients, treatment of critical congenital heart
valve diseases still remains a major challenge and needs to be addressed uniquely
from standard care and treatment of acquired heart valve diseases in adults.
Tissue-engineered heart valves (TEHVs) have the potential to remodel and re-
generate with the patient [7], [8]. This fairly new approach is appealing because of
its potential to allow somatic growth along with continuous adaptation to surround-
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ing physiological conditions in vivo, thereby enabling a replacement that can last for
a lifetime. Pioneering work by Sutherlands group has thus far demonstrated the po-
tential of bone marrow derived stem cells (BMSCs), including extracellular matrix
organization and heterogeneous cellularity of TEHVs similar to native valves [9].Re-
cent studies indicate that the promotion of engineered heart valve tissues by BMSCs
can be regulated by receiving signaling cues from oscillatory shear stress (OSS) with
a simultaneous presence of certain level of physiologically relevant stress associated
with it [2007, Sacks et al; 2010, Ramaswamy et al]. Pioneering studies by Englmayr
group has demonstrated that combine cyclic flexure and laminar flow synergistically
promotes collagen production, a critical ECM protein for heart valve (HV) tissues in
vitro [10]. However, these studies did not explain direct mechanical factors responsi-
ble for collagen production. Primarily, two types of cells are found in heart valves i)
endothelial cells (ECs) and ii) interstitial cells (ICs) which exhibit expression of the
-SMA marker. The ECs cover both sides of the valve surfaces; whereas, ICs populate
the body of the valve cusp and represent a heterogeneous population of cells consist-
ing of family of fibroblast like cells, myofibroblast like cells and smooth muscle cells
(SMCs) [11].A focus of this study is to investigate the potential of human BMSCs to
support the heart valve cell phenotype, specifically by demonstrating concomitant
differentiation to ECs and -SMA expressing cells, both relevant to heart valves, after
exposure to physiologically relevant shear stresses.
1.2 Hypothesis
In vitro cyclic flexure and steady flow condition, in combination, regulate
human bone marrow mesenchymal stem cells to differentiate into heart valve phe-
notypes because of heightened oscillatory shear stress application on growing tissue
2
samples. In addition, physiological range of cyclic flexure and steady flow parame-
ters may provide additional benefits owing to recapitulation of healthy native valve
hemodynamic conditions.
1.3 Specific Aims
1.3.1 Specific Aim 1
Apply oscillatory shear stress (OSS) on a two dimensional (2D) bone marrow
mesenchymal stem cell (BMSCs) mono-layer to observe the changes in cell entities,
such as f-actin and vinculin. F-actin is a cytoskeletal protein, vinculin is a focal
adhesion protein and both are known to respond to shear stresses. After a duration
of 8 days OSS application, cells were evaluated for endothelial cell expression by im-
munofluorescence technique to detect CD31 which is a marker for EC and expressed
on EC surface. The objective of this investigation was to demonstrate that OSS can
promote BMSCs differentiation to endothelial cells (EC).
1.3.2 Specific Aim 2
Apply heart valve relevant mechanical conditions such as steady flow and cyclic
flexure to three dimensional (3D) BMSC-seeded polymer scaffolds to study the ef-
fects of mechanical regulation on engineered tissue growth when stresses are applied
in the physiological ranges.
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1.3.3 Specific Aim 3
Apply heart valve relevant shear stress conditions as in specific aim 2 to 3D
BMSC-seeded scaffolds to investigate gene expression responses and cellular distri-
bution in engineered tissues.
4
CHAPTER 2
Background
2.1 Introduction
This chapter provides a comprehensive review of existing engineering technol-
ogy pertaining to tissue engineered heart valves. A rational approach to heart valve
tissue engineering depends on a thorough understanding of the complexity of biolog-
ically relevant functional elements and their coordinated interactions. Functionality
of the human heart including four valves and the causes of their failures should be
understood. Currently available treatment options such as mechanical heart valve,
bioprosthesis heart valve as well as advantages and disadvantages of these treat-
ments are mentioned. The need of tissue engineering heart valve, current status,
progress and challenges are discussed in depth.
2.2 Anatomy of the Human Heart
Human heart, being the size of an adult fist, is an important organ and is re-
sponsible for pumping blood throughout the body. It beats approximately 100,000
times a day, pumping an average of 2,000 gallons of blood through a network of
60,000 miles of vessels in our body [12], [13], [14]. It is composed of four major
chambers and four valves.
The chambers are called:
i)Right Atrium
ii)Right ventricle
iii)Left atrium
iv)Left ventricle
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Figure 2.1: Anatomy of human heart with four valves and blood flow directions
Atria are the upper compartments whereas ventricles are lower compartments. These
compartments play an important role in regulating blood flow during systole and
diastole.
The cardiac muscle, known as myocardium, contracts and relaxes in each
cardiac cycle. Atria are the upper chambers and function mainly to collect blood,
whereas ventricles are lower chambers responsible for pumping blood. Right atrium
collects deoxygenated blood from various parts of our body via superior and in-
ferior vena cava; right ventricle pumps this blood to lungs; left atrium receives
oxygenated blood from lungs; left ventricle pumps this blood to various part of our
body, initially passing through the aorta. The set of four valves of the heart control
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the unidirectional blood flow. The atrioventricular or AV valves allow only blood
to flow from atria to ventricles. The semilunar valves, the pulmonary and aortic
valve only allow blood to flow from ventricles to out of the heart through the great
arteries [12] (Figure 2.1).
Figure 2.2: Schematic diagram of heart as a blood pumping organ to and from lungs
As shown above (Figure 2.2), a simplified representation of the heart shows
the directionality of the blood flow. The input can be described as a flow of deoxy-
genated blood from the body to right part of the heart, then pumped out to the
lungs and collected in the left part of the heart; finally the output is the oxygenated
blood pumped out to the body. Four heart valves, located inside the heart, play an
important role maintaining unidirectional blood flow during the cardiac cycles.
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Table 2.1: A comparison of cardiac cycles with valve opening and closing events
Systole
(Semilunar valves open and close)
Diastole
(Atrioventricular valves open and close)
a)Contraction in cardiac muscle in the
ventricles is called systole
a) Relaxation in cardiac muscle in the
ventricles is called diastole
b)Both the ventricles contract simul-
taneously and force blood from these
chambers into the arteries to flow blood
out of heart
b) Both the ventricles relax simultane-
ously and make space to accept blood
from the atria
c)Left ventricle empties blood into the
aorta whereas the right ventricle into
the pulmonary artery
c)Left atrium empties oxygenated blood
into left ventricle whereas right atrium
empties deoxygenated blood into right
ventricle
d)Increased pressure due to the con-
traction of the ventricles is called sys-
tolic pressure
d) Decreased pressure due to the relax-
ation of the ventricles is called diastolic
pressure
2.3 Heart valves and valve diseases
The schematic diagram in figure 2.3 illustrates a top view of the four valves of
the heart and their orientation within a heart. Heart valves open and close approxi-
mately 40 million times a year and 3 × 109 times over an average lifetime [15]. These
valves have tissue flaps, called leaflets, which open and close with each heartbeat.
The leaflets facilitate blood flow in the correct direction through the chambers and
to rest of the body.
i) Tricuspid Valve
ii) Pulmonary valve
iii) Mitral Valve
iv) Aortic valve
Aortic, tricuspid and pulmonary valves have three leaflets whereas mitral valve has
two leaflets. While the synchronized opening and closing of valves play an important
role in controlling blood inflow and outflow in heart chambers; disease can occur in
any single or a combination of the four valves. Birth defects, age-related changes,
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infections due to rheumatic fever, or other health conditions can hinder optimal
valve function leading to life threatening conditions. Tricuspid valve closes off the
upper right atrium that holds blood coming in from the body and opens to allow
blood to flow from the top right atrium to right ventricle.
Figure 2.3: Top view cross section of heart with four heart valve
The tricuspid valve also prevents the back flow of blood from the ventricle
to the atrium when blood is pumped out of the ventricle to pulmonary artery. The
pulmonary valve closes off the lower right ventricle and opens to allow blood to be
pumped from the heart to lungs through the pulmonary artery, where it receives
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oxygen. This valve is prone to pulmonary valve stenosis and regurgitation. The
mitral valve closes off the upper left atrium collecting the oxygen-rich blood coming
from lungs and opens to allow blood to pass from upper left side to lower left atrium
eventually venting to the left ventricle. Degeneration of this can lead to mitral valve
prolapse, regurgitation or stenosis. Aortic valve closes off the lower left ventricle
that holds the oxygen-rich blood before it is pumped out to the body and opens
to allow blood to leave the heart from the left ventricle to the aorta and back into
the body. Degeneration of this can lead to aortic regurgitation or aortic stenosis.
Broadly, there are three basic types of HV Disease:
i) Regurgitation
ii) Stenosis
iii) Atresia
Regurgitation or backflow occurs if a valve doesnt close tightly, leaking
blood back into the chambers rather than flowing forward through heart or into an
artery. Stenosis occurs if the flaps of a valve fuse together causing narrowing of
valve opening. As a result, not enough blood flows through the valve. Some valves
can have both regurgitation and stenosis problems. Atresia occurs when a valve is
absent and hence lacks an opening for blood to pass through.
Heart valve disease that develops before birth is called congenital heart
valve disease and often involves improper formation of pulmonary, mitral or aortic
valves. These valves may not have enough tissue flaps, wrong size, shape, or may lack
an opening through which blood can flow properly. Acquired heart valve disease
usually involves aortic or mitral valves. Although the valves are normal at first
problems may develop over time. Both congenital and acquired heart valve disease
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can cause stenosis or backflow. This can make the heart work harder and affect its
ability to pump blood in a long run. If left untreated in critical cases, heart failure
may result.
Figure 2.4: A pictorial representation of diseased and normal heart valves; a) mitral
regurgitation, b) aortic stenosis, c) atresia , d) normal porcine heart valve (Photo-
graph taken in TEMIM lab)
2.4 Clinically available treatments
Primarily there are two types of valve replacement procedures available in clinic.
i) Mechanical Heart Valve (MHV)
ii) Bioprosthetic heart Valve (BHV)
MHV prosthetics are designed to replicate the function of a natural valve. Available
MHV include a) caged ball, b) tilting disc, c) single leaflet d) bi-leaflet mechanical
valve types, which are shown in Figure 2.5. This conventional valve technology is
very mature with well described performance criteria. With improvements in sur-
gical techniques and technologies, mortality during first surgery have been reduced
to 1%. However, a need for reoperation involves high risks with mortality as high
as 20%. MHV are more durable, however patients need a lifelong anticoagulant
medication to avoid thrombosis [16].
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BHV are derived either from human or animals. For example, allograft
or homograft are derived from human cadavers, whose heart has healthy valves.
The homograft is stored frozen and implanted without any other chemical prepa-
ration and often without any tissue type matching. In some cases diseased aortic
valve is replaced with the persons own pulmonary valve (i.e. autograft) and a pul-
monary allograft (valve taken from a cadaver is then replaced with the patients own
pulmonary valve; known as Ross Procedure). Xenografts are the implants derived
from bovine or porcine percutaneous tissue. Both the porcine and bovine valves are
treated with glutaraldehyde before implantation. There are generally three types of
bioprosthetic valves available commercially: a) porcine xenograft valves, b) bovine
pericardial valves, and c) allograft or homograft valves (Figure 2.6). BHV used
in HV replacement generally offer functional properties such as hemodynamics, re-
sistance to thrombosis that are more similar to those of native valves. Currently
available BHV include stented porcine bioprosthetic, stented pericardial biopros-
thetic, stent less porcine bioprosthetic, percutaneous bio- prosthetic expanded over
a balloon and self-expandable percutaneous bioprosthetic [3]. For example, dura-
bility of the Edwards pericardial valve, perceived by many to be the most durable
bioprosthesis, is close to 20 years [17], [18].This life span is equivalent to the aortic
valve homograft which, because of its excellent longevity, is considered by many to
be highly useful for conventional valve replacement in adults [16], [19].
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Figure 2.5: Schematics of different types of prosthetic mechanical valves: Caged ball,
tilting disc,single leaflet, bi-leaflet mechanical valve; Left column displays valves in
open state and right column displays in close state
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Figure 2.6: A schematic representation of bioprosthetic heart valve: left column
displays valve in open state and right column displays in close state (11) . Actual
images corresponding to the schematics are shown as: (A) a porcine bioprosthetic
valve xenograft, (B) bovine pericardial valve, and (C) human aortic valve allograft,
also called a homograft.
2.5 Limitations of MHV and BHV
Patients with mechanical heart valve prostheses may experience valve thrombo-
sis and subsequent systemic embolism, for which they are treated with oral antico-
agulant therapy [5].Embolism occurs due to lodging of a blood clot in bloodstream,
creating a blockage that may affect a part of the body at a distant location such as
brain. Endocarditis, the inflammation of the inner layer of the heart involving the
heart valves is another cause of failure of MHV. In addition, anticoagulant-related
hemorrhage may occur, requiring periodic dose of anticoagulants to prevent throm-
boembolism [20]. Complications of prosthetic valves include primary valve failure
that may occur abruptly from tearing or breakage of components or from a thrombus
suddenly impinging on leaflet mobility. In summary, MHV can trigger life threat-
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Table 2.2: A comparison between MHV and BHV
MHV BHV
• Thrombogenic, Patients need lifelong
anticoagulant medication after implan-
tation
• Resistance to thrombosis
• Systemic embolism • Less thromboembolism than MHV
•Durable (20- 30 years) • Diminished durable ( 5 years)
•Valve hemodynamics compromised •Supports native valve Hemodynamics
•Calcification Resistance •Prone to calcification
•No immunological problem •Immunological Rejection
•Commercially available •Lack of availability of Homo-
graft/Allograft
•Size does not cause much of a problem •Need for multiple surgical procedures
for pediatric patients
•No stenosis •Stenosis is more common
•Contamination or hematogenous
spread occurs more
•Ring abscess, purulent pericarditis,
and myocardial abscesses are much less
frequent in BHV endocarditis
ing complications such as prosthetic valve endocarditis, prosthetic valve thrombosis,
thromboembolism, and mechanical hemolytic anemia. BHV failure usually starts
with calcifications and structural deterioration [21]. Degradation without calcifica-
tion has also been observed in non-chemical treated cryopreserved allografts [22].
MHV replacement has been available for more than six decades and BHV replace-
ment has been available for more than four decades. However, these valves are
unable to grow, repair, or remodel and can be susceptible to infection. These char-
acteristics have significantly limited their adaptability, durability and longevity for
treatment of critical congenital valve diseases in pediatric patients [23].
2.5.1 Tissue Engineered Heart valve
TEHV, in theory, would be a viable option for children with congenital heart
condition. Every year 87,000 children born in the United States and more than
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275,000 children worldwide need heart valve replacement surgery [24]. Among these
children with critical valvular disease, MHV does not provide the best option due to
its requirement of anticoagulant. Other available option in form of BHV are prone
to rapid calcification [22]. Also, the approach such as oversized valves that demands
multiple surgeries in pediatric patient fails to deliver a prolonged solution as these
valves and its conduits are vulnerable to stenosis. Lack of adaptability to pediatric
patients hemodynamic environment is an intrinsic limitation of existing mechan-
ical and biological prostheses, necessitating the requirement of multiple invasive
procedures. Mechanical valves are the prosthesis of choice for children heart valve
diseases. These valves prevents somatic growth and the regimen of appropriate an-
ticoagulation medication is controversial for pediatric population. Studies reported
that morbidity and mortality is significant in mechanical valve replacement in pedi-
atric patients [25].On the other hand TEHV has tremendous potential in satisfying
the criteria of a substitute heart valve, including its ability to address the issue of
somatic growth [26]. In order to be a substitute to existing prosthetic options, tis-
sue engineered heart valve (TEHV) must satisfy some stringent criteria such as its
adaptability to patients hemodynamic environment to function adequately through
a normal human life time. This requires the valve to be made of non-thrombogenic
living tissue. It must possess remodel in a healthy manner and provide the intrinsic
function of facilitating uni-directional blood flow. It should be designed to support
rapid and complete closure without creating any obstruction to blood flow. Finally,
it should facilitate somatic growth of the patient [15].
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Table 2.3: Required design objectives and characteristics
of replacement valves.
Feature to optimize Conventional methods Tissue engineered
Closure of leaflets Resistance to throm-
bosis
Rapid and complete
Fluidic function Good Potentially identical to native
valve in terms of effective ori-
fice area and pulmonary and
systemic pressure and flow lev-
els
Size of orifice area Less than that of nat-
ural valves
Better
Mechanical properties Stable Stable
Surgical insertion Easy and permanent Easy and permanent
Surgical considera-
tions
Sterility, design, and
implantation proce-
dures well established
Sterility,Practical consider-
ations in cell sourcing, Im-
plantation Suturing/physical
handling
Risk of thrombosis Yes, especially me-
chanical valves, which
require anticoag-
ulation, causing
vulnerability to hem-
orrhage
No; endothelial surface to in-
hibit thrombogenesis
Continued on next page
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Table 2.3-continued from previous page
Feature to optimize Conventional methods Tissue engineered
Risk of structural dys-
function
Degradation of syn-
thetic materials rare
with mechanical
valves, resistant to
degradation and
calcification Tissue
degradation and cal-
cification of leaflets
with bioprosthetic
valves
Resistant to degradation and
calcification
Risk of Infection Ever present Resistant to infection
Viability None Yes, able to repair injury, re-
model, and potentially grow
with patient
Cellular function None Physiological VIC and VEC
function
Continued on next page
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Table 2.3-continued from previous page
Feature to optimize Conventional methods Tissue engineered
Tissue function Durable and stable,
chemically inert, non-
hemolytic
Durable and stable Functional
anatomic characteristics: col-
lagen, elastin, GAG distri-
bution and structure Func-
tional mechanical characteris-
tics: anisotropy, high tensile
strength, low effective flexural
rigidity, Remodel according to
need Somatic growth
In vivo monitoring re-
quirements
Standard hemody-
namic functionDegen-
eration/regurgitation
Hemodynamic conditions over
initial and long-term remod-
eling periods Cellular physio-
logical and phenotype, mass
and content levels Changes in
tissue components and mass
changes Structure and me-
chanical properties Differences
between neonate, juvenile, and
adult
Continued on next page
19
Table 2.3-continued from previous page
Feature to optimize Conventional methods Tissue engineered
Geometry Set by design (me-
chanical/pericardial
bioprosthetic) or tis-
sue source (porcine
bioprosthetic)
Designed at time of implant-
based patent-specific geometry
2.6 TEHV Definition
Originating in 1960s as tissue culture technique to populate skin cells and as
a skin graft method in 1970s, tissue engineering have matured into a field of its
own with contribution from scientific as well as clinical results. Being formally
recognized in 1987, tissue engineering has experienced significant progress in past
two decades [16]. The application of scientific principles to the design, construc-
tion, modification, growth and maintenance of living tissue is among one of several
definitions of tissue engineering as this area encompasses interdisciplinary research.
However, an alternative and more complex definition is also available in a report
presented by NIH, the Food and Drug Administration (FDA), and other government
agencies in World Technology Panel Report [27], which states that the application of
principles and methods of engineering and life sciences to obtain a fundamental un-
derstanding of structure-function relationships in novel and pathological mammalian
tissues and the development of biological substitutes to restore, maintain or improve
tissue function [16]. According to Vesely, tissue engineering relevant to heart valves
is defined as the manipulation of biological molecules and cells for the purpose of
creating new valvular structures capable of metabolic activity. Mendelson proposed
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a successful tissue engineered valve and its components must not only accommo-
date those deformations but also have ongoing strength, flexibility, and durability,
beginning at the instant of implantation and continuing indefinitely thereafter, pos-
sibly despite an evolving tissue architecture. Therefore, an engineered tissue valve
should have the fundamental biophysical and biochemical similarities of a native
heart valve. The next section describes the details of the native valve properties as
a reference.
2.7 Heart valve development, maturation, adaptation, and
repair: key information for TEHV
Developmental Biology provides a thorough understanding of biology, physi-
ology, and pathophysiology of heart valves, which is critical for tissue regeneration.
This knowledge may be informative and provide opportunity to recapitulate criti-
cal components for valve engineering. During embryological development, the three
germ layers ectoderm, endoderm, and mesoderm give rise to cells that differentiate
to form the bodys tissues and complex organs. The heart develops primarily from
the embryonic layer called mesoderm [28]. A complex signaling pathways initiate
the conversion of mesodermal cells to cardiac lineages. Cardiac myocytes become
organized and form linear heart tubes that eventually becomes loops, and with
development of septa heart achieve its multi-chambered configuration. During car-
diac development endothelial cells lining the inside surface undergo an epithelial to
mesenchymal trans-differentiation and form called cardiac jelly to become precur-
sors of mature valve interstitial cells (VICs) [29]. It is well accepted that epithelial
mesenchymal transitions depends on cell-cell and cell-matrix interactions. Many
different signaling pathways, growth and transcriptional factors (including vascular
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endothelial growth factor [VEGF], nuclear factor in activated T cells [NFATc1], and
Notch) regulate the process of heart valve formation [30]. Studies have reported that
maturation and evolution of human semilunar valves in fetuses, neonates, children,
and adults are different. Adult valves are fully matured and organized compared to
fetal valves. Immature activated cells in fetal valves are capable of dynamic adapta-
tion to structures. Initially HV architecture, collagen content, and organization of
ECM are immature compared with that of adult valves [31]. VIC express character-
istics of myofibroblast-like phenotype, express α-SMA, MMP-13, and SMemb, and
continuously remodel the ECM during fetal HV development. The cells transition
to a quiescent state in the normal valve after birth, which suggests a progressive
adaptation to the profound hemodynamic environment. The cell density progres-
sively decreases (by nearly 90%) throughout life [30]. For targeted treatment of
heart valve disease, it is critical to understand the role of valve endothelial cell and
VICs in valvular wound healing, adaptation, and remodeling. This information is
important in selecting the type of cells that should be used for engineering a valve.
Normal and pathological cardiac valves respond to environmental conditions, such as
mechanical loading, by cell activation and matrix remodeling. Studies have shown
that VIC return to their normal quiescent fibroblast phenotype after undergoing
remodeling and repair in an in vivo implant [32], [33], [34]. These findings suggest
that a tissue engineered valve can gain guided differentiation, adaptation, remod-
eling and regeneration after implant, however the suitable cell type, scaffold type,
chemical and mechanical conditioning should be clearly identified [30].
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2.8 Heart Valve structural properties
Heart valve is a unique type of tissue comprised of extracellular matrix, cells
with negligible presence of blood vessels and nerves. The valve ECM is made up of
structural components such as, collagen, elastin, glycosaminoglycans (GAGs) and
valve interstitial cells (VICs), endothelial cells (EC). Each component contributes
to the unique properties of valve; for example: collagen provides strength and stiff-
ness to maintain coaptation during diastole, when cusp has maximal area; Elastin
extends in diastole, contracts in systole to minimize cusp area; GAGs accommodate
shear of cuspal layers, cushions shock during valve cycle; VICs synthesize ECM; EC
maintain non-thrombogenic blood-tissue interface and regulate immune and inflam-
matory reactions [35]. Microscopically, the aortic valve is composed of three distinct
layers: (1) the ventricularis closest to the inflow surface, rich in elastin, (2) the fi-
brosa closest to the outflow surface, primarily composed of densely packed collagen,
and (3) the centrally located spongiosa, largely composed of glycosoaminoglycans
(GAGs). Together, collagen, elastin, and GAGs comprise the valvular ECM [30].
In vivo, heart valve leaflets experience a dynamic and complex mechanical stress
state during every cardiac cycle: sheer stress due to blood flow (open valve), flexure
(opening and closing), and tension (closed valve) [36]. It is becoming more scientifi-
cally proven and acceptable that valvular endothelial cells (VEC) are responsible for
non-thrombogenic blood-tissue interface and regulate immune as well as inflamma-
tory reactions. EC isolated from vascular and valvular sources display differences
in gene expression and other properties, which is a major indication of endothe-
lial cell heterogeneity [37]. Heart valve endothelial cells are different from those in
the aorta [38], [39]; for example, in response to mechanical stress, porcine aortic
valve endothelial cells align perpendicular to flow whereas endothelial cells from the
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aorta align parallel to flow and their gene expression is different from that of aortic
endothelial cells exposed to the same mechanical environment. These differences
suggest a unique phenotype of VEC not mimicked by vascular cells and could have
implications for cardiovascular cell biology and cell-source considerations for tissue-
engineered heart valves. Moreover, different transcriptional profiles are expressed
by the endothelium on the aortic side versus ventricular side of normal adult pig
aortic valves [40]. On the other hand, VIC is the most numerous valvular cell type
and responsible for ECM synthesis and secretes ECM degrading enzymes, metallo-
proteinase (MMPs), and their inhibitors (TIMPs). These biochemical combinations
mediate matrix re- modeling [31], [41]. Besides all the mentioned properties, addi-
tionally, VIC include a dynamic population of resident cells of diverse and dynamic
phenotypes such as fibroblast like cells to myofibroblast-like cells; it is believed that
their phenotype is regulated by biochemical as well as biomechanical conditions.
Tissue samples from adult heart valves in situ reveals that VIC shows a dormant
state and ex- hibits a fibroblast-like phenotype, characteristic of intermediate fila-
ments and is detected by the presence of a cell marker called vimentin and a very
low levels of α-SMA. In fact, less than 5% of normal adult VIC express α-SMA
and in quiescent state, which is a characteristic genetic marker of myofibroblast-like
function. Myofibroblasts are a version of activated fibroblasts responsible for ECM
synthesis, which in turn facilitate tissue remodeling. Interestingly, previous in vitro
studies in which isolated cells were cultured from heart valves, demonstrates 56% to
78% of cells with α-SMA marker [37] [41]. This suggests that removal of cells from
the environment of the intact valve or their manipulation stimulates VIC [30].
It is hypothesized and scientifically becoming more significant that biome-
chanical and biochemical factors play an important and potentially synergistic role
in determining the local homeostatic environment of the aortic VIC. As demon-
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strated in in vitro studies, application of mechanical stimulation such as tension
and addition of cytokine stimulation such as TGF-1 were found to synergistically
alter the contractile and biosynthetic proteins of aortic VICs to a greater extent
than each factor alone [36]. The need for mechanical stimulation and/or cytokines
and potentially other soluble factors for the maintenance of appropriate cellular
biosynthetic activity are proposed as the key ingredients for valve tissue engineering
efforts. In the present research, the focus is on biomechanical regulations of bone
marrow derived mesenchymal stem cells which support the valvular phenotype.
2.9 Tissue Engineering Heart Valve Methodology:
Researchers have suggested tissue-engineered heart valves to be the ultimate
solution for treating valvular heart disease. An ideal TEHV would be able to respond
to growth and physiological forces in the same way that the native valve does,
whereas existing valve implants only replace a diseased or defective native valve.
These valves are either derived from metal, polymers or fixed tissues which are
unable to adopt the biological processes. However, a tissue engineered valve would
be a living organ. Two main approaches have been attempted over the past 10 to
15 years;
I. Regeneration
II. Repopulation
Regeneration is the process in which a resorbable matrix or scaffold, either acellular
or seeded in vitro with cells (e.g. stem cells) is implanted in situ. It is expected that
the implant will remodel over a period of time and eventually yield a functional valve
composed of native cells and de novo tissues. In this approach it is believed that the
patients cells will migrate to the scaffold and secrete extracellular matrix. Whereas,
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Table 2.4: Proposed Pathway for TEHV
.
Basic requirements
and Involved Steps
Pathway In vitro
(Conventional
Paradigm)
Pathway In vivo
(Modified Paradigm)
Required Elements Exogenous Cell Scaffold Circulating Precursor
cells (Endothelial and
Mesenchymal) Scaffold
In vitro Phase (Con-
struct)
In vitro maturation in a
bioreactor
Not Required
In vivo Phase Engineered tissue and
derivatives of seeded cells
and/or new cells in vivo
remodeling
Engineered tissue and
derivatives of seeded cells
and/or new cells in vivo
remodeling
in repopulation a whole porcine or bovine acellular aortic valve is implanted in situ.
In this case the implanted tissue mostly remain intact which provides a me-
chanically sound connective tissue matrix foundation for tissue building over the
time. In this case the cells of the patients are also expected to migrate and hence
repopulate the acellular matrix. It is hypothesized that this model can create liv-
ing tissue which has the complex microstructure necessary for proper function and
durability of the valve [16].The subtle differences between regenerate and repopulate
strategies thus have to do with:
i) In vitro seeding of cells
ii)Use of a synthetic scaffold versus a decellularized bio-scaffold
2.10 Scaffold
Both chemical and mechanical factors can regulate cell biosynthesis ECM pro-
duction [42], [43], [44], [45], [46]. Native tissues experience multi-scale modes of de-
formation which trigger biochemical stimuli which determine physiologic responses.
To activate viable tissue regeneration and reproduction in tissue engineering ap-
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proaches, recapitulation of mechanical properties of complex multi-scale native tis-
sue architectures, the cascade biological phenomena, and some level of detail of
mechanical deformation (in case of heart valves) are critical. It is a huge chal-
lenge to replicate a substrate that possess all biological, chemical and mechanical
properties of native tissues; however an optimum condition substrate or scaffold
should be identified for tissue engineering purposes. To mimic native tissue struc-
ture and organization, it is first necessary to develop techniques to produce scaffolds
in a controlled manner with characteristic lengths on a scale comparable to those
observed in nature. For example, mechanical regulation of cell function can be reg-
ulated with geometrically modulated elastomeric substrates [47]. Scaffold designing
requires desired chemical, physical, and mechanical characteristics in a controlled
and reproducible manner. Physical characteristics such as, surface texture play an
important role in promoting cell attachment. A highly porous microstructure is re-
quired to allow tissue ingrowth, and an interconnected porous network is required to
allow adequate nutrient transport and cytokine activity. Above all scaffold should
maintain desired mechanical properties. Currently available long continuous fiber
structures with a fiber diameter of native ECM collagen fibers in the range of 50nm
to 1000 nm approximate the local cellular environment adequately. An organized
formation of fiber structures make them appropriate for load handling such as these
encountered during cyclic tensile or bending states. Xenograft or homograft are
animal or human derived valve tissues respectively. In this type of materials chemi-
cal procedures are performed to decellularized the ECM with a minimal damage to
the tissue structure. Homografts are limited by availability. With the benefits of
native tissue like regeneration and growth after implantation, xenografts possess the
risk of zoonoses (i.e. diseases can communicate from animals to human). Synthetic
biodegradable polymers polymers such as: polyglycolic acid (PGA), polylactic acid
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Table 2.5: PGA:PLLA (synthetic scaffold) used for Heart Valve Tissue regeneration
(46)
.
Year, Reference Material/Polymer Outcome.
1996, Shinoka et al. Polyglycolic acid fiber
matrix Biodegradable
In vivo Lamb Model
2005, Sutherland et al. Polyglycolic acid
and polylactic acid
Biodegradable
In vivo, Sheep model
2006, Engelmayr et al. Polyglycolic acid
and polylactic acid
Biodegradable
In vitro FSF bioreactor
2010, Ramaswamy et al. Polyglycolic acid
and polylactic acid
Biodegradable
In vitro CFF bioreactor
(PLA), poly-4-hydroxybutyrate (P4HB) and polycaprolactone (PCL) are currently
used in laboratory investigations as scaffold substitutes.
This section includes a brief discussion on the mechanical behavior of
the synthetic scaffold for tissue regeneration. Many different approaches have been
adopted to design scaffolds for heart valve tissue engineering; for example fabrication
of synthetic and native tissue derived procedures [48], [49], [50]. These scaffolds can
be classified into polymeric scaffolds, native ECM scaffolds and collagen or fibrin
gel scaffolds. Although there has been good progress in all these approaches, the
synthetic, polymeric scaffolds have to date received the most attention [15].
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Table 2.6: Synthetic scaffold used for Heart Valve Tissue regeneration (46) by trade
name
.
Year, Trade Name, In
vivo or In vitro
Material/Polymer Outcome
1967, Biomer, Elasthan,
Bovine
Polyether urethanes 1. Better hydrolytic sta-
bility. 2. Oxidative
degradation of the soft
segment. 3. Environ-
mental stress cracking
1980, Thoralon, Rat Silicone in backbone of
polyether urethane
1. Siloxane end groups:
(a) Give protection to the
polyether soft segment
(b) Provide low strength
1990, ChronoFlex, Bion-
ate, In vitro and in rabbit
Polycarbonate urethane 1. More stable than PEU
2. Crack resistant 3.
Susceptible to hydrolysis
1991, PurSil, Carbosil,
Rabbit
Silicone end groups and
midblocks with polyether
or polycarbonate ure-
thane
1. Increased resistance to
oxidation
1996, ElastEon, In vitro
and in sheep model
Silicone midblocks and
polyether urethanes
1. Good biostability
1997, ChronoFlex C, In
vitro
Silicone midblocks and
polycarbonate urethanes
1. High strength 2.
Hydrolytically and prote-
olytically stable
2005, Seifalian, In vitro Polyhedral oligomeric
silsesquioxane integrated
poly(carbonate urea)
urethane
1. High strength, elastic-
ity at high levels of stress
2. Resistance to degrada-
tion 3. Reduced calcifica-
tion 4. Reduced platelet
Adhesion
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2.11 Cell sources
Different types of cells have been used for experimental purposes in vivo as
well as in vitro. Table below is a description of cells with their advantage and
disadvantage of their usage. Ample cell availability can sometimes be a limitation.
However, advanced biological techniques and cell culture, proliferation protocols are
solving these obstacles. Progress has been made over the past few decades to identify
a suitable cell source, scaffold material and guided signaling cues.
Table 2.7: Cell sources and properties table included in supplemental section(46,
47)
2.12 In vivo and clinical approach
This approach can be perceived as being more attractive because in this proce-
dure there is no need for in vitro tissue culture and this can simplify the replacement
procedure to a great extent. This approach relies on natural regenerative potential
of the body. A nonthrombogenic, nonimmunogenic functional scaffold capable of
host cell repopulation and remodeling is the key to this approach. Native ECM
scaffold (decellularized xenografts, homografts) implants have shown exciting tissue
regeneration in juvenile sheep and dog models [51], [52]; however it is not clear if
it can be translated to human counterparts. Some investigation are promising in
adult patients, but immunogenic response and graft failure are reported in children
patients [53].Results are dependent on the techniques of decellularization and use of
chemicals on the treated matrix. Recent reports have suggested deoxycholic acid-
treated porcine xenografts provide endothelial coverage of pulmonary valve intimal
surface after 10 months in humans [54]. Even though early sign of tissue regenera-
tion occurs both in homografts and xenografts, but when compared to conventional
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cryopreserved homografts, no clear benefits in functionality were observed at one
year follow up. Use of synthetic scaffold at the implant site has several advantages
over native scaffolds. These materials can be modulated for chemical and mechan-
ical properties. Cellularization and tissue regeneration has been found in animal
models [55], [56], [57], [58], [59], [60].Different approaches such as scaffold surface
conditioning with bio molecules to enhance cell attachment, combining autologous
cells with scaffold or use of a peritoneal cavity as a bioreactor have also proposed and
currently under study [61].However, these approaches are not yet verified whether
they render the correct cell phenotypes in neo valve tissue. In a single human patient
clinical study Dohmen et al. reported excellent in vivo repopulation of valve tissue
after implant. In this study a Ross procedure was performed in a 63 year adult male
patient and a healthy recovery was observed. However this study along with other
study agrees that glutaraldehyde preserved heart valves degenerate more rapidly in
young patients than older patients. An increased calcium turn over in case of young
patients limit these approach for long term viability as an implant [62].
2.13 Challenges of in vivoHV engineering approaches
In vivorepopulation and regeneration mentioned earlier represents a quick,
inexpensive and on-demand approach; however translation of this approach to a
clinical application faces several challenges. It is well accepted that after implanta-
tion native decellularized or synthetic scaffolds achieve cellularity due to presence
of circulating endothelial progenitor cells present in blood or originating from bone
marrow, neovascularization and adjacent tissue. However, according to previous
studies most animal models may be inappropriate for studying these phenomenon
and may not be clinically relevant [63], [64]. Use of decellularized xenografts in
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human studies presents controversial results. The main challenge is to unlock the
guided pathways of repopulation in vivo and to obtain valve relevant cells for ap-
propriate functionalities.
2.14 In vitro approaches(Bioreactors, an engineered device)
In vitro tissue engineering combine the biomechanical and biochemical condi-
tions in an In vitro tissue culture phase. Scaffold materials and cell sources are
basic building blocks for tissue formation in these environments. Bioreactor is an
engineered device often used in tissue engineering laboratories to culture, grow or
monitor tissues regeneration. These devices are designed to maintain a sterile envi-
ronment that is necessary to culture biological samples. A suitable environment is
achieved and maintained that ideally should reproduces the physiological environ-
ment (including biochemical and mechanical functions) specific to the tissue that is
to be regenerated. Bioreactors can also be used during maturation of the regener-
ating tissue for studying and understanding the biological factors influencing tissue
regeneration. There are commercially available bioreactors used in laboratories;
however, requirements for new culture environments and mechanical conditioning
demands improved designs. Scientists and Engineers are making a conscious efforts
to improve and better match the native biological surroundings in order to un-
derstand the fundamentals of tissue regeneration. Bioreactors have been designed
and used for the mechanical conditioning of tissue engineered cardiovascular con-
structs; for example: vascular grafts [65], [66], myocardial patches [67], and heart
valves [68], [69]. These instruments typically rely on fluid flow in the form of media
supplements to generate a physiological or nonphysiological biomechanical environ-
ment. Use of these devices have been demonstrated to promote extracellular matrix
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elements resulting in improved tissue mechanical strength [65], [66], [69]. Increased
cellular function within these tissue engineered constructs also reported [66]). This
research being presented here is interested in studying the effects of dynamic me-
chanical stimulation on the development of TEHVs. Previous studies have used
cyclic flexure stretch, and flow (FSF) bioreactors to exhibit both independent and
coupled stimulatory effects [70], [71], [72], [73] on tissue regeneration.Organ level
conditioning of tri-leaflet heart valves have been reported for augmentation of col-
lagen content compared to previous studies [74].It has been well accepted that even
simple deformation modes can have a profound effect on forming heart valve tissues.
2.15 Challenges of in vitro HV engineering approaches
Bioreactors possess vast implications for the development of functional tissue
regeneration; however small sample capacity, anatomical sample geometry, and cou-
pled mechanical stimuli are some of the limitations of current generation bioreac-
tors. For robust and statistically significant results, it is important to regenerate
ample number of samples. Therefore, most bioreactor studies are limited by sta-
tistical significance. Very few customized bioreactors have been designed and used
in laboratory environments for precise study of the individual or combine effects of
mechanical stimulation on engineered valve tissues. Ease of handling starting from
tissue culture, assembly of equipment in sterile condition for long term studies are
some critical challenges for this study. Sample analysis at multiple time points, and
accommodation of simple sample geometries amenable to subsequent mechanical
testing are limited and need to be improved [15]. Mol et al. suggests the lack of
knowledge for generating elastin network in valve tissues which should be addressed.
It is well accepted that elastin is a critical component in HV and yet no bioreactor
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Table 2.8: Current generation Bioreactors based on mechanical stimulation for heart
valve tissue regeneration (64).
Authors, Year Type of Bioreactor Parameters studied
Hoerstrup et al., 2000
(56)
Dynamical stress in-
duced by flow
Effects of pulsed flow vs
steady flow
Dumont et al., 2002 (65) Dynamical stress in-
duced by flow and
resistance
Prototype of a compact
pulsatile flow system
Engelmayr et al., 2003
(61)
Combine cyclic flexure
and steady flow
Effects of cyclic flexure
and flow on valve tissue
regeneration
Mol et al., 2003 (66) Increasing cyclic strain Effects of cyclic strain
Schenke-Layland et al.,
2003 (67)
Dynamical stress in-
duced by flow
Repopulation potential
of decellularized valves
Ramaswamy et al., 2010
(63)
Organ level conditioning Pulmonary artery pres-
sure conditions
in vitro system exist that can produce elastin in a laboratory environment [61]. Fi-
nally, implantation of TEHV procedures either by invasive open heart surgeries or
minimally noninvasive approach is not known yet. If a minimally invasive approach
has to be adopted, then valve crimping and deployment should be evaluated.
2.16 Summary of the review articles
A PubMed search on heart valve tissue engineering reveals more than 1000
citations since 1995, more than 30 of which are review articles. Tissue engineering of
heart valves is considered one of the few technologies in the field of tissue engineering
that has tremendous potential for creating tissues analogous to a native human heart
valve, with long sustainability. In spite of being in early stages of development, with
advanced biotechnology and improved biomaterials in conjunction with optimization
of mechanical conditioning, TEHVs have the potential to revolutionize treatment of
critical valve diseases [75].
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Table 2.9: Summary of Literature Review-table included in supplemental section.
2.17 Challenges of TEHV
Advancement in medical procedures have enabled modern civilization to tri-
umph over many life-threatening diseases. The complications considered deadly a
few decades ago can be cured and life can be saved. However, in case of critical heart
valve diseases, survival is still not assured. On one hand, TEHV has tremendous po-
tential, on the other hand the concept is still in infancy. Efforts are in progress, but
the complex nature of heart valve structure, maintenance and functionality require
more scientific as well as engineering insights. The key bioengineering challenge
is to determine how biological, structural, and mechanical factors affect cellularity
and ECM formation; mechanical stimulation plays a vital role in individual tissue
organization and a synchronized stimulation is responsible for in vivo functionality.
These factors are fundamental to any approach toward developing a clinically vi-
able tissue engineered heart valve (TEHV). In current approaches scaffold material,
design, functional viability, biocompatibility and material responses to the hemody-
namic environment are critical. Understanding of cell and sub-cellular events, signal
generation and interpretation are key factors in stem cell based heart valve tissue
engineering. Overall, such approaches need to be structured to address these funda-
mental issues for laying the basis for TEHVs that can be designed and subsequently
for long-term clinical functionality [15].
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CHAPTER 3
Marrow stem cell differentiation for valvulogenesis via oscillatory flow
and nicotine agonists: unusual suspects
3.1 Introduction
Fluid-induced oscillatory shear stress (OSS) and Nicotine are known antago-
nists in cardiovascular disease. However, from a regenerative medicine standpoint,
we hypothesized that these parameters may support the cell differentiation of bone
marrow mesenchymal stem cells (BMSCs) for engineering heart valves. Thus in this
study, OSS and Nicotine (10-6M) were applied individually to BMSCs in monolayer
culture. In both cases, a significantly higher expression of CD31 was detected com-
pared to corresponding controls (p < 0.05). We interpret that both OSS and Nico-
tine independently support mesenchymal to endothelial transformation. However,
the underlying mechanism for this transformation in terms of the cell cytoskeletal
structure was entirely different between the two stimulants. In the case of OSS,
F-actin filaments exhibited a stretching response and formed a preferential align-
ment with each other. However, in the Nicotine-treated group, there was clearly
an increase in the number of actin filaments present which led to the maximum ex-
pression of CD31 in comparison to the OSS and control groups. From our findings,
we speculate that while Nicotine may stimulate an increase in the differentiation of
BMSCs to endothelial cells, OSS may play a greater role in cellular distribution,
and the eventual creation of a tissue engineered heart valves (TEHV) endothelium.
Since 1960s, treatment of diseased heart valves (HV) has achieved tremendous
success in improving the survival results for adults as well as pediatric patients
[76], [77], [78] , [79].Surgery enables replacement of mechanical heart valves (MHV)
and bioprosthetic heart valves (BHV) to treat severe HV anomalies [1], [80], [81].
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MHVs exhibit robust durability; however life-long anticoagulant intake is required
to minimize the risk of thrombus [5].On the other hand, premature structural break-
down as well as calcification is the major limitation for BHVs [3], [82]. Owing to
somatic growth pediatric patients suffering from severe heart valve disease in par-
ticular often require complex, multistep, valve replacement surgical procedures. A
tissue engineering approach may potentially overcome current treatment limitations
for the pediatric patient requiring valve replacement and may also serve as a per-
manent treatment strategy [23], [51].Conceptually, (TEHV) can be constructed by
combining a polymeric matrix scaffold seeded with stem cells which can differentiate
into heart valve cell types, i.e., depicting a valve interstitial cell phenotype within
the tissues and a surface, valvular endothelium. For this reason, research efforts
have focused on establishing suitable biomaterials and potential cell sources that
can yield optimized TEHV properties for implantation. On one hand, human em-
bryonic stem cells (hESC) possess the potential to differentiate into the three germ
layers, including gut epithelium (endoderm); cartilage, bone, smooth muscle, and
striated muscle (mesoderm) as well as neural epithelium, embryonic ganglia, and
stratified squamous epithelium (ectoderm) [83] . However due to ethical constraints
and limitations in supply, hESCs are not a practical cell source. On the other hand,
human induced pluripotent stem cells (iPSC) also possess the ability to differentiate
into the three germ layers in vitro; however the slow kinetics and low efficiency of
reprogramming methods to generate human iPSC as well as a real risk of teratoma
formation [84]impose major limitations on their utility [85]
Adult stem cells have generated significant interest in both the clinical
and basic scientific community due to their immune modulatory characteristics and
their ability to transdifferentiate into different cell types [86] . Very frequently,
mesenchymal stem cells (MSCs) can be extracted from several sources such as adi-
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pose tissue, peripheral blood, skeletal muscle, umbilical cord blood, placenta and
bone marrow [87] . In heart valve tissue engineering, bone marrow derived mes-
enchymal stem cells (BMMSCs) have been extensively investigated [88], [89] . A
few key studies are summarized here: BMMSC-based tri-leaflet TEHVs were pre-
viously developed in a bioreactor in vitro and demonstrated morphological and
mechanical properties similar to human native heart valves [90].Meanwhile, Suther-
land et al successively demonstrated that tissue engineered heart valves (TEHV)
can be created from ovine BMMSCs and function satisfactorily in vivo for four
months [9]. The valves exhibited extensive tissue remodeling in that timeframe and
eventually resembled native heart valve histological features, with recapitulation of
the through-thickness valvular layers. Mechanically, heart valves experience cyclic
flexure, tensile and fluid-induced shear stresses during their lifetime [91] . The dis-
ruption of hydrodynamic forces was shown to produce dramatic cardiac defects in
zebra fish, including failure of valve formation, an absence of heart looping and
the formation of a third chamber [92] . Moreover, shear flow has been reported
to promote endothelial cell (EC) differentiation of MSCs [93], [94] and cardiac dif-
ferentiation of embryonic stem cells [95]. In addition, bioreactor-based mechanical
pre-conditioning of engineered heart valve constructs have been shown to be critical
in promoting robust tissue formation from BMMSCs, which is likely to be impor-
tant in augmenting the construct properties prior to implantation [74]. However the
extent to which BMMSCs can support heterogeneous valvular cell differentiation, in
particular, growth of a valve endothelium is still not conclusive. In line with these
observations, the focus of this study was to evaluate the effects of one mechanical
and one biochemical stimulant on BMMSCs differentiation towards the heart valve
lineage. For the mechanical factor, oscillatory shear stress (OSS), which is innately
present during native valve dynamics, was applied to BMMSCs growing in 2D mono-
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layer culture. OSS has previously been hypothesized to be an important mechanical
metric for heart valves [96] , [97] . For the biochemical factor we hypothesized that
a small concentration of Nicotine (10-6M) which has previously served to promote
vasculognesis may potentially promote a valvular endothelium for BMMSC-derived
tissue engineered heart valves [98], [99], [100], [101], [102], [103] . Ironically, both
OSS and Nicotin are known antagonists in cardiovascular disease; yet we postulated
that these unusual suspects would have a beneficial effect in promoting mesenchy-
mal to endothelial transformation, which in turn would support the formation of an
engineered valve endothelium.
3.2 Materials and Methods
3.2.1 BMMSC Culture
Human BMMSCs were purchased (Fisher Scientific, Pittsburgh, PA, passage 1)
and cultured in T75 cell culture flasks until ∼95% confluence. MSC culture medium
with supplemental growth factors (Thermo Scientific HyClone AdvanceSTEM Mes-
enchymal Stem Cell Expansion Kit) was used to culture expands the BMMSCs for
seven days.
BMMSCs in Low Dosage Nicotine Supplement
BMMSCs were cultured in a 24 well plate with Dulbeccos Modified Eagle
Medium (DMEM), 10 percentage Fetal Bovine Serum (FBS) and 1percentage peni-
cillin and streptomycin (Fisher Scientific) for 10 days. Twelve wells were treated
with 10-6M Nicotine whereas another twelve wells were cultured without Nicotine.
Media was changed every four days for all 24-wells. Immunostaining was performed
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on four of the wells for each group to visualize F-actin, Vinculin, and CD31 under
florescent microscope.
BMMSCs under OSS environments
A microfluidic channel (Bioflux200 system; Fluxion Biosciences, San Francisco,
CA) was used to permit OSS conditioning of BMMSC monolayer culture. The man-
ufacturers protocol (www.fluxionbio.com) was followed in order to permit adhesion
of BMMSCs inside the channel. A 48 well, low shear (0-20 dyne/cm2 plate with a
channel 350um wide, 4.8mm long was used to culture the cells in no stress (NS) and
OSS environments (n = 12 wells/group). Regular basal medium DMEM, 10percent-
age FBS, 1percentage penicillin/streptomycin (Fisher Scientific) was used to culture
BMMSCs for 8 days. Continuous medium flow was regulated from input well to out-
put well by a pneumatic pump controller. Cells were exposed to steady flow for six
days which included a ramp up protocol (Fig.3.1a) followed by OSS conditions for
an additional 48 hours that was induced by a physiological shear stress waveform
(Fig.3.1b) [104]. This ramping process was necessary to improve cell attachment
to the bottom wall of the microfluidics channel prior to OSS conditioning. Confir-
mation of robust BMMSC attachment was observed after eight days of shear stress
exposure (Fig.3.1c), i.e., six days of increasing steady shear stress followed by two
days of OSS.
Computational Model of OSS in Microfluidic channel
To quantify the magnitude of oscillatory conditions the cells were exposed to,
a computational fluid dynamic (CFD) analysis of the media flow past the microflu-
idic channel in which the cells were attached to was performed. In brief, the fluid
domain of the rectangular channel was drawn and discretized (Ansys commercial
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software, Ansys Inc, Canonsburg, PA). The CFD set-up included the physical prop-
erties of the cell culture media with a density = 1.01 g/cm3 and a dynamic viscosity
of 1.27cp as previously reported [105]. At the inlet a physiologically valid velocity
waveform was imposed. The outlet was set to zero relative pressure and all walls
were set to non-slip conditions. A convergence criteria of 1x10-6 was used for both
momentum and continuity equations. Simulations were run in a Hewlett Packard
work station with an intel(R) Xeon(R) CPU, x5550@ 2.67GHz (2processors) with
16.0 GB installed memory and 64-bit Windows 7 operating system. Independence
tests were performed on the mesh, time step and periodicity for steady and pulsatile
simulations accordingly. A 5% error acceptance criterion in comparison with highly
resolved simulations (spatially, temporally, and three cycles) for the wall shear stress
variable was used in the selection of the finalized mesh, time step and periodicity
parameters which were: i) mesh: structured type -10, 916, 96 nodes and 10,080,00
quadrilateral elements, time step: 2 ms and periodicity: 2nd cycle. Finally to quan-
tify the oscillatory environment, the oscillatory shear index (OSI) was calculated
based on the previously reported definition by He and Ku [106], wherein an OSI =
0 represents complete uni-directional flow whereas an OSI = 0.5 represents fully os-
cillatory flow. The OSI calculation on the microfluidic channel surface to which the
cells were adhered to revealed a very uniform and a maximum level of oscillations,
with an OSI ∼ 0.5 everywhere on the channel surface.
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Figure 3.1: a)Ramping protocol involving a six day step-wise increment in steady
shear stress to permit BMMSC acclimatization to the channel flow environment; b)
Continuous pulsatile wave form adapted from a physiological flow waveform which
was used to impart OSS to the BMMSCs for 48 hours. c) Longitudinal optical
microscopy of adhered cells to the bottom surface of the microfluidic channel over
an eight day timeframe. The BMMSCs appeared to have adhered well after gradual
augmentation of steady shear stress followed by OSS conditions were prescribed
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3.2.2 Immunofluorescence Staining
Immunostaining of F-actin, vinculin, and CD31 were performed on the samples
exposed to Nicotine after ten days. The staining was also repeated to BMMSCs
exposed to an increasing steady shear stress for six days followed by two days of
high OSS conditions (OSI ∼ 0.5). The following staining procedure was prescribed:
BMMSCs were washed twice with pre-warmed, phosphate-buffered saline (PBS,
Thermo Scientific* HyClone* Dulbecco’s Phosphate Buffered Saline, pH 7.4) and
fixed with 4% paraformaldehyde for 15-20 minutes at 4oC. After fixation cells were
washed three times for 5-10 minutes each with PBS. Then 0.1% Triton X-100 was
applied to enhance immunostain permeability to the cells for 3 to 5 minutes followed
by washing three times for 5-10 minutes with PBS. Blocking of nonspecific epitopes
was performed by adding 1percentage goat serum in PBS for 2030 minutes.
F-actin
Nicotine and non-Nicotine samples (n=4) were treated with Cyto Painter F-
actin Staining Kit Red Fluorescence conjugated Phalloidin (Abcam) next day. Sam-
ples were incubated for 30-60 minutes at 4oC. Cells were rinsed gently with PBS
2 to 3 times to remove excess dye. PBS was added to the wells to avoid drying
during imaging under the microscope. A similar processing protocol was performed
for the microfluidic OSS samples except that a steady shear stress of 1 dyne/cm2
was applied to add and remove the reagents at each step.
Vinculin
Cells were incubated with dilute primary antibody (mouse monoclonal anti vin-
culin, Thermo Scientific) to a working concentration in blocking solution overnight
at 4oC. Next, the cells were washed three times for 5-10 minutes each with PBS.
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Dilute Flurophore-conjugated isotype specific secondary polyclonal antibody (Goat
anti-Mouse IgG (H+L), DyLight 488) (Fisher Scientific) was added and incubated
for 30-60 minutes at 4oC. Cells were rinsed gently with PBS 2 to 3 times to remove
excess dye and PBS was added to avoid drying of cells during imaging.
CD31
For CD31 cell surface marker detection, the permeability step was omitted; in-
stead, cells were directly incubated with dilute primary antibody (mouse monoclonal
anti CD31, Abcam) to a working concentration in blocking solution overnight at 4oC.
Cells were washed three times for 5-10 minutes each with PBS. Dilute flurophore-
conjugated isotype specific secondary polyclonal antibody (Goat anti-Mouse IgG
(H+L), DyLight 488, Fisher Scientific) was added and incubated for 30-60 min-
utes at 4oC. Cells were rinsed gently 2 to 3 times to remove excess dye and PBS
was added to avoid drying of cells to obtain images of CD31 under Olympus IX81
fluorescence microscope.
Image analysis
Signal intensity values for CD31 images (sample size, n = 4) were quantified
using the following protocol (ImageJ, NIH; Bethesda, MD). A rectangular region of
interest (ROI) with an area of 7840 pixels was defined. Three such different ROIs
(replicates, r = 3) with maximum intensity were selected and measured. Average
intensity of the ROIs was recorded in arbitrary units (AU). Care was taken to avoid
any false positive signals.
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Statistical Analysis
Independent t-tests were performed using SPSS (IBM, Armonk, NY) to com-
pare CD31 expression level for NS and OSS group as well as Nicotine and non-
Nicotine groups (n =4 samples/group). OSS or Nicotine-treated groups were com-
pared against their respective control groups wherein a significant difference was
interpreted to occur at p <0.05.
3.3 Results
Cell cytoskeletal and membrane protein changes were assessed after an eight
and ten day treatment protocol of shear stress mechanical conditioning and nicotine
treatment of BMMSCs respectively. The shear stress protocol included six days of
augmenting shear stress, followed by two days of highly oscillatory shear environ-
ments (OSI ∼ 0.5). Owing to the application of OSS to BMMSCs in our studies,
our interest was primarily aimed at identifying the F-actin alterations within the
cytoskeleton and the changes in vinculin along the BMMSC membrane. This was
because these cellular constituents in addition to talin and certain specific integrins
are known to respond to the surrounding mechanical environment, thereby promot-
ing events such as stem cell differentiation and subsequent, gene expression [107].
We restricted our evaluation of changes observed for these proteins to the posi-
tive expression of CD31, an endothelial cell surface marker, as an early indicator
of mesenchymal to endothelial transformation of BMMSCs under OSS or Nicotine
exposure.
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3.3.1 F-actin staining
BMMSCs exposed to OSS
A noticeable axial stretch pattern of actin filaments in BMMSCs exposed to
OSS was observed compared to the NS (control) condition. Morphologically, the cells
appeared to be elongated whereas cells were randomly oriented and not elongated
under the NS condition (Fig.3.2).
Figure 3.2: Immunofluorescence staining for F-actin (red) of BMMSCs cultured
under No Stress (NS) (column1) and OSS (column2) condition for eight days in the
microchannels. A distinct stretching pattern of F-actin filaments was observed after
exposure to OSS compared to NS counterpart.
BMMSCs exposed to Nicotine
An increase in the presence of actin filaments were observed in the group con-
sisting of BMMSCs treated with a low-dose of Nicotine 10-6 M in comparison to the
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untreated group (Fig.3.3). However, unlike the cells exposed to OSS, a random ori-
entation with no preferred F-actin alignment was observed in the Nictoine-treated
samples and its corresponding control group.
Figure 3.3: Immunofluorescence staining for F-actin (red) in BMMSCs cultured
without Nicotine (column1) and with Nicotine 10-6 M, column 2) in a 24 well plate
for 10 days. No visible stretching pattern in F-actin was observed in either of these
groups. However, an increase in the number of actin filaments was clearly visible in
the Nicotine treated group in comparison to its corresponding control, i.e., untreated
group.
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Figure 3.4: Immunofluorescence images of BMMSCs cultured under NS (column1)
and OSS (column2) in the microchannels for eight days. An absence is preferential
cell membrane distribution in vinculin was observed in both the OSS and corre-
sponding control groups
Vinculin staining
BMMSCs exposed to OSS
A higher density of vinculin adhesion molecules along the cell membrane was
not observed in NS and OSS samples, nor could distinct focal adhesion points be
identified in either group; rather, a random distribution in positive staining (green)
was observed throughout the cells (Fig.3.4).
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Figure 3.5: Immunofluorescence images of BMMSCs cultured without Nicotine (col-
umn1) and with Nicotine (10-6 M, column 2) for 10 days. An absence is preferential
cell membrane distribution in vinculin was observed in both the untreated and
Nicotine-treated groups.
BMMSCs exposed to Nicotine
Preferential vinculin staining was absent along the cell membrane of the Nico-
tine treated and untreated groups after ten days of culture and was found to occur
randomly in both groups. Similar to the results observed for the OSS-treated cells,
vinculin was observed to be spread-out throughout the BMMSC cytoplasm in both
the nicotine treated and untreated samples (Fig.3.5).
49
CD31 staining
The expression of cluster of differentiation 31 (CD31) (also known as platelet
endothelial cell adhesion molecule (PECAM1)) has been previously suggested to
demonstrate differentiation of BMMSCs to highly angiogenic and vasculogenic cells
for cell-based strategies to treat ischemic cardiovascular diseases [108]. Thus we
investigated for positive expression of CD31 in BMMSCs treated with exposure to
either OSS or Nicotine and subsequently quantify the level of CD31-derived positive
signal intensities by image analysis. BMMSCs exposed to OSS.
BMMSCs exposed to OSS
An approximate threefold increase in the expression of CD31 was observed
in BMMSCs that were exposed to two days of pure OSS environments (OSI ∼ 0.5)
following a six-day steady shear stress ramp up protocol. Moreover, the results of the
image analysis demonstrated a significant difference (p <0.05) in CD31 expression
between the cells exposed to OSS and its corresponding NS-control group (Fig.3.6).
Table 3.1: Number,Orientation and Length of actin filaments in control, OSS and
nicotine groups.
Actin filament Control OSS Nicotine
Count (number)
Average 8.00 2.33 15.33
SDV 2.41 1.08 4.75
SEM 1.39 0.62 2.74
Angle (Deg)
Average 22.12 8.98 41.66
SDV 14.75 5.52 28.83
SEM 8.52 3.19 16.65
Length (AU)
Average 259.52 479.39 228.75
SDV 93.35 256.16 92.79
SEM 53.90 147.89 53.57
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(a)
(b)
Figure 3.6: a) Immunofluorescence staining for CD31 expression by BMMSCs under
NS (column1) and OSS (column2) conditions after 8 days of culture within the
microfluidic channel environment. b) Quantification of positive staining (green;
from images in part a)) for CD31 signal-intensity in NS and OSS groups; Samples
exposed to OSS expressed a significantly higher level of positive CD31 (p<0.05) in
comparison to the control group.
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BMMSCs exposed to Nicotine
A greater than threefold increase in CD31 positive staining was found in BMMSCs
cultured for 10 days in media containing a low dose (10-6 M) of Nicotine compared
to untreated controls (Fig. 7). Moreover, a significant difference (p<0.05) in CD31
expression was found between the two groups
3.4 Discussion
BMMSCs have demonstrated great potential for heart valve tissue engineer-
ing [109]. However, the differentiation-specific mechanisms due to optimized bio-
chemical and biomechanical factors are yet to be completely delineated. Therefore,
further investigation on the biomechanical and biochemical factors that can enhance
functional engineered heart valve tissues originating from BMMSCs is warranted.
Previous studies suggested that the fluid-induced shear stresses play a predomi-
nant role in eliciting robust tissue formation when compared to solid (flexural and
tensile) valve-relevant stresses, since the scaffold used could only allow for modest
levels (up to 7%) of strains [74]. In addition, it was noted that there was a high
degree of OSS associated with specimen deformation during the combined steady
flow-cyclical flexure event, which was analogous to the closure of valve leaflets .
Interestingly, OSS is innately present in native heart valves (particularly on the
arterial side of the leaflets), and is presumed to enhance valve coaptation [110].
Thus, from a physiologically relevant cellular mechanics standpoint, the oscillatory
nature of shear stresses may play a major role within a regenerative framework, by
triggering appropriate BMMSC signaling events that lead to enhanced engineered
heart valve tissue formation. Indeed it is likely that the physiological mimicry of the
nature of flow oscillations rather than the similitude of the shear stress magnitudes
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(a)
(b)
Figure 3.7: Immunofluorescence staining for CD31 expression by BMMSCs under
Nicotine-untreated (column1) and Nicotine-treated (column2, 10-6 M) conditions
after 10 days of culture within 24-well plates. b) Quantification of positive stain-
ing (green; from images in part a)) for CD31 signal-intensity in Nicotine-untreated
and Nicotine-treated groups; Samples exposed to low dosage of Nicotine (10-6 M)
expressed a significantly higher level of positive CD31 (p <0.05) in comparison to
the untreated, control group.
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themselves may be more critical for cell and tissue development, since previous find-
ings have demonstrated that robust BMMSC-derived tissue production was achieved
even under sub-physiological flow conditions [10].
Elsewhere,studies [111], [112], [113] have already shown that OSS regulates
the differentiation capabilities of BMSMCs towards osteogenic, adipogenic and chon-
drogenic pathways. While flow-stretch-flex stress environments are coupled for the
native heart valve, it may not be practically possible for this coupled effect to be
routinely applied prior to implantation, nor may all aspects of this environment
be necessary to produce an optimal construct. Instead, further understanding of
the role of specific biomechanical cues such as OSS on tissue production and cell
differentiation from suitable cell sources such as BMMSCs may be more practical.
Meanwhile, endothelial based nicotinic acetylcholine receptors (nACHRs)
have been systematically shown to be involved in angiogenesis, and in particular
the α7 nACHR homomer [100] , [101], [102] , [114], [115]. Initial activation of an
angiogenic pathway can either be endogenous via the agonist acetylcholine or by
the external stimulant, Nicotine. Extensive subsequent studies by the Cooke group
at Stanford have shown that the fundamental mechanism by which Nicotine in low
doses (10-8 to 10-6 M) promotes endothelial cell migration, proliferation and tube
formation is the augmented permeability of Ca2+ into the cell cytoplasm again via
modulation of α7 nACHR( [101], [114], [115], [116] ). This in turn activates kinases
responsible for heightened EC activity. At a different scale, Nicotine also enhances
endogenous growth factor production by the cells, such as FGF, NO and endothe-
lin [117] that are involved in angiogenesis. Therefore, while OSS and Nicotine can
provoke arterial plaque formation, we hypothesized that the natural occurrence of
OSS in native valves and in enhancing engineered tissue formation, as well as the
induction of vasculogenesis by Nicotine could contribute beneficially towards struc-
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tural and phenotypic changes of BMMSCs that support the heart valve phenotype.
With respect to the phenotypic characteristics, we investigated the potential of
BMMSC-based mesenchymal to endothelial transformation rather than mesenchy-
mal to fibroblastic or smooth muscle cell differentiation since the former is likely
to be more challenging, while the latter has already been conclusively shown in
previous studies [10] . As a first step in this endeavor, an understanding of the
cellular structural response to external biomechanical and biochemical factors may
correlate to a specific set of desirable cell differentiation events in support of the
heart valve phenotype. It has been demonstrated that F-actin as well as vinculin,
talin and some other specific integrins may contribute to structural and morpholog-
ical changes in ECs due to shear [107] , [10] , [118] . In the case of OSS, a highly
stretched appearance in the actin filaments was observed. In this regard, we found
that OSS conditioning and a low dosage of Nicotine (10-6 M) exposure to BMMSCs
altered the F-actin structure. In the case of OSS, a highly stretched appearance
in the actin filaments was observed. This pointed towards direct alterations in the
BMMSC cytoskeleton due to OSS, which in turn may lead to unique gene expres-
sion activity. Moreover we found that OSS conditioning tended to promote some
degree of alignment of actin filaments with respect to each other compared to the
no flow (controls) condition (Fig.3.2). The BMMSC response to OSS was strikingly
similar to actin filaments in the cytoskeleton of arterial ECs wherein, cell elongation
and flow alignment events were also observed [119] , [120] . Thus our findings to
this point suggested early evidence of BMMSCs responding to OSS in an EC-like
manner.
On the other hand, augmentation of actin filaments was clearly observed
in low-dose, Nicotine-supplemented samples (10-6 M) in comparison to untreated
controls after 10 days of culture (Fig.3.3). Observed individually but interpreted in
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combination, these microstructural changes in the BMMSC cytoskeleton that were
caused independently by OSS and Nicotine external stimuli are likely to modulate
(to varying degrees) cellular gene expression and eventual protein synthesis. For
example, the increased number of F-actin filaments in Nicotine treated cells may
serve to control regulatory pathways of genes which have previously been found to
occur via nACHRs in ECs [98] , [100].
We decided at this preliminary stage to focus on EC differentiation of
BMMSCs by positive detection of CD31, a well-established EC surface marker. Our
motivation for selecting this EC marker derived from previous work demonstrating
that BMMSCs robustly express CD31 after successfully undergoing mesenchymal to
endothelial transformation [108] . Indeed, preliminary structural changes observed
in F-actin filaments after OSS exposure seemed to be a precursor for regulating dif-
ferentiation of BMMSCs to ECs after OSS exposure, as this mechanical stimulant
significantly (p<0.05) increased CD31 positive expression (Fig.3.6). The significant
increase (p<0.05) was also observed independently by the treatment of BMMSCs to
a low dose of Nicotine (10-6 M); however in this event, the mechanism of increased
EC differentiation appeared to have been prompted by an increase in the number of
F-actin filaments, rather than changes in filament orientation and stretching. No-
tably the magnitude of CD31 expression after Nicotine treatment was the highest
compared to OSS and control groups (Figs.3.6 and 3.7). Thus, even though both
OSS and Nicotine independently serve to enhance the differentiation of BMMSCs
to ECs, we interpret that Nicotine may serve to robustly augment CD31 expression,
while OSS may eventually serve to preferentially align and distribute cells on the
surface of TEHV constructs to create a distinct endothelial layer, i.e., a valve en-
dothelium.
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Our study has several limitations: firstly, we conducted our experiments in
2-dimensional cell monolayers. Undoubtedly 3D cell-scaffold interactions will have
unique effects on mesenchymal to EC differentiation of BMMSCs. Furthermore, we
focused on cell structural changes that elicited BMMSC to EC differentiation, but
did not target specific gene expression activity directly regulated by either OSS or
Nicotine that led to the phenotypic change. For example, it was shown that OSS
directly modulated the normal expression of the gene klf2a during valvulogenesis
whereas an absence of klf2a produced defective heart valves [96]. Thus, OSS is
essential for normal valve development and is likely to be important in BMMSC-
derived TEHV development as well. Secondly, we only tested for one EC marker,
and perhaps more importantly, did not specifically target the valve EC phenotype.
This could be readily achieved for example by determining the positive expression
of nucleoside phosphorylase and an absence of Interleukin-1 alpha which are distinct
characteristics of valve ECs (as opposed to vascular ECs) [39] . Finally, the com-
bined effects of low dose (10-6 M) Nicotine and OSS regulation of BMMSCs may
have synergistic benefits; however this remains to be determined. These issues are
currently being addressed by our on-going research efforts in the area of BMMSC
biomechanics, for the purposes of enhancing treatment through cardiovascular re-
generative medicine approaches.
In summary, we examined the effects of two unusual suspects in the form
of OSS and low dose (10-6 M) Nicotine for enhancing BMMSC differentiation to
ECs. Specifically, we examined the F-actin filaments and vinculin components of
BMMSCs after independent exposure to OSS and Nicotine. In both cases, no ob-
servable differences were seen in the arrangement of vinculin molecules along the cell
membrane in comparison to untreated control counterparts. However, preferential
alignment and stretching of F-actin filaments occurred after OSS exposure, whereas
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the number of filaments themselves was clearly augmented when Nicotine was ap-
plied. All of these alterations to the filaments within the cytoskeleton resulted in
significantly enhanced (p <0.05) BMMSC differentiation to ECs in comparison to
untreated controls. Based on the results obtained in the current study, we speculate
that Nicotine may serve the role of heightening the level of EC expression whereas
OSS may promote the creation of a TEHV endothelium. We further believe that the
regulation of F-actin filaments by OSS and Nicotine to enhance the differentiation
of BMMSCs to ECs is a fundamental, yet important finding that can be leveraged
to generate necessary cell (e.g. ECs, smooth muscle cells) and tissue (i.e. collagen,
glycosaminoglycans, elastin) heterogeneity in TEHVs, and in a broader context, is
likely to offer protocol optimization in other areas of cardiovascular medicine as well.
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CHAPTER 4
Physiologically-relevant flexure and flow induces valvulogenesis in stem
cell-seeded scaffolds
4.1 Introduction
Post-fetal heart valve development is intimately connected to local hemody-
namic conditions. For treatment of heart valve disease, prosthetic valves perform
fairly well in most adults; however, for pediatric patients, there is the added re-
quirement that the replacement valve grows with the child, thus extremely limiting
current treatment options. Tissue engineered heart valves (TEHV), such as those
derived from autologous bone marrow stem cells (BMSCs), have the potential to re-
capitulate native valve architecture and accommodate somatic growth. However, a
fundamental pre-cursor in promoting directed integration with native tissues rather
than random, uncontrolled growth requires an understanding of BMSC mechanobio-
logical responses to valve-relevant mechanical environments. Here, we report on the
responses of human BMSC-seeded polymer constructs to the valve-relevant stress
states of: (i) steady flow alone, (ii) cyclic flexure alone, and (iii) the combination
of cyclic flexure and steady flow (flex-flow). BMSCs were seeded onto a PGA:
PLLA polymer scaffold and cultured in static culture for 8 days. Subsequently,
the aforementioned mechanical conditions, (groups consisting of steady flow alone -
850ml/min, cyclic flexure alone - 1 Hz, and flex-flow - 850ml/min and 1 Hz) were
applied for an additional two weeks. We found significant expression (p <0.05)of the
transcription factor klf2a, by the BMSCs under flex-flow conditions, which is known
to be critical in valve development. We interpret that this was likely due to the pres-
ence of both appreciable fluid-induced shear stress magnitudes and oscillatory shear
stresses, which were concomitantly imparted onto the samples. Additionally, under
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flex-flow states, we found significant expression (p <0.05) of the YARS gene, known
to be expressed by valvular but not vascular endothelial cells.Finally, samples from
the flex-flow group exhibited a valve-like distribution of cells that expressed endothe-
lial (preference to the surfaces) and myofibroblast (preference to the intermediate
region) phenotypes.These results indicate that flex-flow mechanical environments
support directed in vitro differentiation of BMSCs uniquely towards the heart valve
phenotype as evidenced by cellular distribution and the expression of specific ge-
netic markers. A priori guidance of BMSC-derived, engineered tissue growth using
flex-flow states may serve to subsequently promote controlled, engineered to native
tissue integration processes in vivo needed for successful long-term valve remodeling.
Heart valves play an important role in controlling unidirectional blood
flow. However, birth defects or infections (e.g. rheumatic fever) can cause one or
more of the heart valves to malfunction, which may lead to critical valve anomalies
in children. Advances in implant design and surgical techniques have substantially
augmented the success of prosthetic heart valves in adult patients. However, the ef-
ficacy of these implants is severely limited in pediatric patients due to their inability
to promote somatic growth and valvular tissue remodeling; as a result, multiple ma-
jor surgeries and re-operations are commonplace, which places a significant health
burden on the growing child.
Similar to native valves, a tissue engineered heart valve (TEHV) has the
ability to adapt and evolve with the living host and is conceptually considered a
permanent solution to treating heart valve disease [16]. During each cardiac cy-
cle, native valves are continuously subjected to mechanical stresses from the flow of
blood; for example, aortic valve leaflets experience peak fluid-induced shear stresses
of approximately 5-6 dyne/cm2 in mid systole [121], [122], [110].
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Mechanical stimuli, when applied to developing cardiovascular tissues, al-
ter gene expression-promoting tissue remodeling events, which in turn enhances spe-
cific mechanical and phenotypic characteristics. Native heart valves are subjected
to highly complex cyclic, tensile and fluid-induced stresses [110].In an engineered
heart valve tissue context, mechanical stimuli, particularly those that incorporated
fluid-induced shear stresses, have enhanced progenitor cell differentiation pathways
and construct tissue properties for the valve application [123] , [124] [125], [38]. For
example, Hoerstrup et al. performed experiments using a pulsatile flow bioreac-
tor device that enhanced TEHV tri-leaflet structures with ∼300% increase in the
collagen extracellular matrix (ECM) content compared to statically cultured coun-
terparts. Elsewhere, bioreactors have been built to couple any combination of flow,
cyclic stretch and cyclic flexure (FSF bioreactors), which have also verified that
coupled mechanical stimuli significantly promote ECM production, in particular,
the combination of steady flow with cyclic flexure [105], [10]. Of particular rele-
vance to heart valves, Vermot et al. showed that blood flow-induced oscillatory
shear stresses (OSS) directly modulate the normal expression of a transcription fac-
tor from the kruppel-like factor gene family, klf2a in a zebra fish model. The klf2a
gene is critically involved in valvulogenesis, whose absence results in defective heart
valves [96]. The generation of a functional TEHV has remained elusive in part,
due to a lack of information regarding the mechanobiological events necessary to
optimize the in vitro culture process. Nonetheless, under mechanical guidance, tis-
sue engineering feasibility studies have thus far demonstrated that native valvular
cells can recapitulate valve structure with adequate mechanical strength and mor-
phology [126], [127], [23], [51], [128]. In addition, non-valvular cells, such as bone
marrow stem cells (BMSC), saphenous vein endothelial cells (ECs), ascending aorta
myofibroblasts and umbilical cord-derived cells, have exhibited increased produc-
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tion of valvular ECM, DNA content and endothelization in vitro under mechanical
conditioning states [129], [130], [131], [132], [133], [74] . BMSCs in particular
have shown considerable promise for heart valve tissue engineering, as they are mul-
tipotent stem cells with a minimal risk of immunogenicity, are void of ethical/legal
concerns and can be obtained and culture-expanded easily; typically, BMSCs can be
isolated, purified and expanded to a large number in a matter of days [134].BMSCs
maintain extensive differentiation, proliferation and clonogenic capacity in vitro.
Human BMSCs respond to mechanical conditioning and have been shown to pro-
duce heart valve ECM components in vitro, [90], [135]. Engelmayr et al [10], [136],
described pioneering work on elucidating the effects of combined cyclic flexure and
steady flow states (flex-flow), which served to significantly promote engineered col-
lagen in de novo engineered heart valve tissues derived from BMSCs. However, a
fundamental precursor to TEHV studies evaluated at the tissue scale is the need to
understand the process by which valve-relevant mechanical stimuli can regulate cell
fate, particularly cell differentiation in the context of stem cell sources. Thus, in this
study, our primary goal was to determine unique responses of BMSCs to flex-flow
conditions in the promotion of valvulogenesis.
4.2 Methods
4.2.1 BMSCs Culture and eExpansion
BMSCs isolated from human bone marrow, characterized and tested with stro-
mal, stem, and hematopoietic marker, were purchased in frozen vials (Fisher Sci-
entific, Pittsburgh, PA). Cells were recovered from dry ice packaging, and were
immediately thawed and diluted with a pre-warmed culture medium to reduce the
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toxic effects of cryopreserve reagents upon arrival. Approximately 5 × 105 cells were
transferred to a T75 vented cell culture flask and placed in an incubator supplied
with 5% CO2 at 370C with 95% humidity. Flasks were fully confluent at 1 week. An
average of 2 x 106 cells were obtained at each passage. Freshly prepared stem cell cul-
ture medium with 10% advanced stem cell undifferentiated growth supplement, 1%
penicillin and streptomycin (Thermo Scientific HyClone, Fisher Scientific)medium
was used for cell culture and expansion. An aseptic cell and tissue culture environ-
ment was dedicated for the entire duration of the experiment. BMSCs at passages
6 to 8 were utilized for subsequent tissue engineering experiments.
Scaffold Preparation and Cell Seeding
An equal ratio of poly-glycolic acid (PGA) and poly-L-lactic acid (PLLA),
nonwoven polymer felt was utilized as the scaffold material (Biofelt, Biomedical
Structures, Warwick, RI) [137], [130], [10]. Specimens measuring 17 mm long, 6
mm wide and 1 mm thick (n= 12) were cut and two metallic springs were carefully
attached to either end of the scaffold. This assembly was required for dynamic tissue
culture in our customized U-shaped bioreactor device(Fig.4.1). Prior to cell seeding,
scaffolds were gas sterilized with ethylene oxide (EtO; AN 306, Anprolene, Ander-
sen Products Inc, HawRiver, NC) for 12 hours and treated 70% ethanol. Aeration
procedures were performed as per the recommendations described in the manufac-
turers instruction guide [138] . The following protocol was used to complete the
seeding procedure: Approximately 90% confluent flasks were rinsed with Dulbeccos
Phosphate-Buffered Saline (DPBS, Fisher Scientific) buffer. Next, 0.25% trypsin
and ethylenediaminetetraacetic acid (EDTA) solution were added and incubated at
370C for 3 minutes. An equal volume of serum was used to neutralize the trypsin
solution. Cell suspensions were collected in15 ml conical tubes and centrifuged at
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1700 rpm for 5 minutes. A cell pellet was retrieved by removing the supernatant
and was suspended with freshly prepared tissue culture media for further usage. A
single scaffold was seeded with 2 x 106 BMSCs and suspended in 20 ml of tissue
culture media in 50 ml vented conical tubes (Product#TP87050, TPP, TubeSpin
Bioreactor, Zollstrasse 7, CH-8219 Trasadingen, Switzerland). The tissue culture
media comprised of Dulbeccos modified Eagles medium (DMEM, Fisher Scientific)
supplemented with 10% fetal bovine serum (Atlanta Biologics, GA, USA), 1% peni-
cillin and streptomycin (Thermo Scientific HyCloneTM; Fisher Scientific), 2ng/ml
basic fibroblast growth factor (bFGF, CorningTM; Fisher Scientific) and 82 µg/ml
ascorbic acid 2 phosphate (AA2P, Sigma-Aldrich). Subsequently, these tubes were
placed in a rotisserie (LabquakeTM Rotisserie Hybridization Rotators, Thermo scien-
tific, USA) at 8 RPM inside a cell and tissue culture incubator. Media was changed
every two days and the BMSC-seeded scaffolds were cultured under rotisserie culture
for a total timeframe of 8 days.
4.2.2 Tissue Engineering Experiments
Beyond the first 8 days of rotisserie culture, samples were randomly assigned
to one of four different treatment groups and underwent an additional period of
tissue culture for 14 days. These groups were (n = 12 specimens/group): 1) No flow
(Static Controls), 2) Steady flow-alone (Flow), 3) Specimen cyclic Flexure-alone
(Flex) and 4) combination of steady flow and specimen cyclic flexure (Flex-Flow).
For the mechanical conditioned groups, a custom built U-shape bioreactor which
been previously described extensively was used [105]. This device is connected to
a peristaltic pump and an environmentally sealed linear actuator for experimental
purposes. The experimental set-up consisted of four identical conditioning chambers,
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with each chamber containing 3 samples. Specimens were fixed with a pin one
end while the other side was to a circular moving post. For Flex and Flex-Flow
experiments, the moving post was moved linearly in the axial direction to initiate
specimen cyclic flexure using the linear actuator (frequency of 1 Hz). For the Flow
and Flex-Flow cases, a peristaltic pump (Master flex L/S, model#7523-80, Cole
Parmer, model#7535-04, East Bunker Court Vernon Hills, IL, USA) was used to
maintain a continuous flow rate of 850 ml/min.
a)
b)
Rectangular Sample (shown in red color)
Moving post (Ring)
Fixed post (Pin)
Figure 4.1: a) Schematic diagram of the custom built U-shaped bioreactor connected
to a linear actuator which guides the rods that threads through samples, permitting
them to bend and straighten. b) Inset: shows three samples inside the conditioning
chamber that can be moved one end (ring) and is fixed on the other (pin). In the
current study, the actuator was set to a 1 Hz frequency to permit cyclic flexure while
the pump operated at a steady flow rate of 850 ml/min.
65
4.2.3 Collagen Assay
Specimens from all four groups were removed following 22 days (n=3 per group)
and subjected to collagen biochemical assays (Biocolor life science assays, Carrick-
fergus, County Antrim, UK). Digested collagen samples were quantified similar to
methods described previousl [74]. Samples were digested with a solution of 0.5 M
acetic acid (Sigma) and pepsin (1 mg/ml Pepsin (P7000), Sigma). Digestions were
carried out for 16 hrs on a rocker (Orbitron Rotator; Boekel Scientific, Feasterville,
PA) at 40C. Collagen extracts were then assayed according to the in vitro tissue
procedure provided by Sircol soluble collagen assay kit (Biocolor Ltd.). A multi-
mode microplate reader was (Synergy HT, Biotek instrument, Inc,#7091000) set to
an absorbance of 555 nm to obtain the collagen concentration.
4.2.4 Quantitative real time polymerase chain reaction
After 22 days of tissue culture nascent tissues from the four groups were evalu-
ated for gene expression and quantification. Quantitative real time-polymerase chain
reaction (QRT-PCR) was performed as previously described [139], [140], [82], [141]
. Engineered tissues were washed with DPBS and total RNA was isolated accord-
ing to manufacturers protocol. Briefly, 1ml of lysis buffer was added to 30 mg of
tissue was flash frozen and homogenized with a homogenizer at high speed till no
visible tissue fragments remained in the mixture. A volume of 175 µl of tissue
lysate was transferred to a 1.5 ml micro-centrifuge tube. The pellet was shifted
to a 1.5 ml RNase-free micro-centrifuge tube to perform the RNA isolation. To-
tal RNA was purified with the SV Total RNA Isolation System (Promega). 1µg
of total RNA was used for reverse transcription reaction and the cDNA was syn-
thesized using an oligo (dT) 15 primer provided by GoScript TM Reverse tran-
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scription system (Promega). QRT-PCR was performed using GoTaqqPCR Master
Mix (Promega). Signal intensities were detected with a Step-One Real-Time PCR
System (Applied Biosystems). The PCR mixture contained forward and reverse
primers and SYBR green I dye reagent along with the cDNA obtained from reverse
transcription. The primers and genes were selected from the referred sources and all
primers were purchased (Sigma Aldrich). Primer sequences (Table 1) for YARS, NP,
and klf2a genes were obtained from a quantitative real time PCR primer database
(http://primerdepot.nci.nih.gov/) to amplify the target sequence. Briefly, the con-
ditions used for the experiment were as follows: PCR tubes (Applied Biosystems,
Grand Island, NY) were held at 950C for 2 min before the cycle started to activate
the Taq polymerase. The cycling parameters were 950C for 5 sec; 600C for 45 sec;
950C for 15 sec. The change in threshold cycle (∆Ct) values were averaged and
normalized with GAPDH, an endogenous gene using the ∆∆Ct method described
in the reagent guide (Applied Biosystems) [142]. Expression of gene fold changes
were calculated as 2-∆Ct, and gene expression ratio of four groups (Control, Flow,
Flex and Flex-Flow)) was compared for further analysis.
4.3 Immunostaining
Immunofluorescence (IF) staining of CD31 and α-SMA cell surface proteins
were performed (n=3 specimens/group) after 22 days for evidence of endothelial and
myofibroblastic phenotypes respectively. This study focused on two valve relevant
proteins such as cluster of differentiation 31 (CD 31) and alpha- smooth muscle
actin (α-SMA). CD31 is known to be expressed on the surface of EC and α-SMA in
SMC as well as myofibroblast like cells in valve interstitial cells. Each sample was
sectioned along the tissue and three different layers i.e. top surface layer, deep middle
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Table 4.1: Primer sequences utilized for QRT-PCR analyses in this study
Gene ID Gene Name
F:Forward Primer (5′-3′)
R:Reverse Primer (5′-3′)
GAPDH
Gglyceraldehyde-3 F:AATGAAGGGGTCATTGATGG
-phosphate dehydrogenase[32] R:AAGGTGAAGGTCGGAGTCAA
YARS
Ttyrosyl-tRNA F:CCTCCAAATTGGGCATCTAC
synthetase[34] R: GGAGCTGAGGTGGTAAAGCA
FZD2
Frizzled class F:CGGCCCCGCAGCGCCCTGCCC
receptor 2 [32,35] R:ACACGAACCCAGGA
GGACGCAGGCC
MLC1F
Myosin light F:GAGTTCTCTAAGGAACAGCAGG
chain 1[32,35] R:CTGCGTGTCTTTGACAA
GGAAGGCAATGG
klf2a
Kruppel-like F:CCGTGTGCTTTCGGTAGTG
factor 2a[11] R:AAGAGTTCGCATCTGAAGGC
core layer and bottom surface layer were immunostained with anti α-SMA and anti
CD31 and evaluated for SMC and EC expression. A porcine aortic heart valve was
dissected and assigned as positive control. The valve leaflets were immunostained
for EC and SMC expression following the same protocol.
Tissue sections at room temperature were washed with DPBS and fixed
with 10% formalin overnight, with a 20:1 volume fraction. After fixation, 2 mm by
2 mm tissue sections were cut with the help of a pair of scissors and embedded in
the tissue freezing medium (Catalog # :19636-4, Polysciences, Warrington, PA). To
retain structure, tissues were incubated with the liquid freezing medium at room
temperature in a petri dish for 2 hrs. Next, the liquid freezing medium was also
separately added to plastic molds (Fisher Scientific) and frozen in liquid nitrogen
temperature. A white solid bed of the freezing medium was obtained after ∼ 1
minute. At this point, the prepared tissue section was carefully placed on the frozen
solid bed inside the mold and more freezing medium was added to immerse the
sample. The mold was subsequently snap-frozen in liquid nitrogen. Finally, serial
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sections (12 m thickness) parallel to the tissue surface were cut using a cryostat
microtome (Leica CM3050 S, Buffalo Grove, IL, United States). The following
staining procedure was followed: tissue sections mounted on the glass slides were
treated with 0.1% Triton X-100 for 3 to 5 minutes to enhance the permeability of
the cell cytoplasm (this step was excluded for CD31 staining). Additional washing
steps were performed three times for 5-10 minutes with DPBS. Blocking of non-
specific epitopes was facilitated by adding 1% goat serum in DPBS for 30 minutes.
The primary antibodies used were mouse monoclonal anti-CD31 (ab24590, Abcam,
Cambridge, MA, USA) and mouse monoclonal anti α-SMA (ab18147, abcam, Cam-
bridge, MA, USA). An overnight incubation at 4oC was done. Samples were washed
with wash buffer (DPBS+ 0.01% Triton-X 100) to reduce background. Secondary
antibody (Goat polyclonal anti-mouse IgG (H+L) (DyLight 488) (Fisher Scientific)
with 1% goat serum) was added and incubated overnight at 4oC for both CD31
and α-SMA immunostaining. Glass slides with stained sections were viewed under
a fluorescent microscope (Olympus BX51, Center Valley, PA). For CD31, a depth
of 92 ±10.58 m from the top of the surface was considered as the top layer, a depth
of 76±4 µm from the bottom surface was considered as the bottom layer, and a
264±18.33 µm to 652±17.43 µm depth from the top surface was considered as the
deep middle core layer. Similarly, for α-SMA, a depth of 140±17.43 µm from the
top surface was considered as the top layer, a depth of ∼ 108±12 µm from the
bottom surface was considered as the bottom layer, and a depth of 336±13.85 µm
to 464±21.16 µm from the top surface was considered as the deep middle core layer.
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4.3.1 Computational Fluid Dynamics (CFD)
In order to quantify the fluid-induced stresses imparted on the bioreactor spec-
imens, we conducted CFD simulations. For the cases of flex-flow and cyclic flexure
alone, we incorporated moving boundary analyses; specifics on the CFD approaches
are described in detail in our previous work [97] . The four cases of flow-alone,
cyclic flexure-alone, combined flow and flexure, and no flow were simulated. We
used an inlet velocity boundary condition 0.1067 m/s for the cases of flex-flow and
steady flow-alone, which represented the experimentally prescribed flow rate of 850
ml/min. No slip conditions were prescribed to the bioreactor walls, while the walls
the samples were set equal to the velocity of the grid for the flex-flow and cyclic
flexure-alone. The outlet of the bioreactor was set to a zero relative-pressure bound-
ary condition. All simulations were run utilizing a Newtonian, viscous model, with
laminar flow conditions, with the following fluid material properties: density =
1.01g/cm3 and dynamic viscosity = 1.27 cp (CFx, Ansys Inc., Canonsburg, PA).
The results were analyzed after a convergence criterion of 1x10-9 set for each of the
momentum, continuity, and mesh displacement equations was satisfied. All simu-
lations were conducted in a Hewlett Packard work station with intel(R) Xeon(R)
CPU, x5550@ 2.67GHz (2 processors), with 16.0 GB installed memory and 64-bit
Windows 7 operating system.
In order to denote the coupled effects of shear stress magnitude and the
temporal oscillations in the flow, we utilized an oscillatory shear index (OSI)-scaled
shear stress magnitude (OSI- |{~τ |) which we previously defined as: [97]. OSI- |{~τ | =
2 × OSI × TSSM. Where TSSM is the time-averaged shear stress magnitude. The
OSI [97] itself is defined by:
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OSI =
1
2
(1−abs(
∫ T
0
τdt)∫ T
0
abs(τ)dt
Where, |{~τ | is the fluid-induced shear stress, T is the period and t is time. The
OSI ranges from 0 to 0.5; an OSI of 0 represents unidirectional flow while an OSI
of 0.5 signifies a high degree of temporal oscillations in the flow.
4.3.2 Statistical Analysis
One way analysis of variance was conducted to test any significant differences
between the four groups investigated for collagen production and gene expression
outcomes (n = 3 samples/group/outcome) . A Tukeys post hoc test was subse-
quently performed to determine significant differences between groups. All statis-
tical analyses were conducted using the statistical package for the social science
(SPSS) software (V16, IBM, Armonk, NY). Significant differences between groups
were observed to have occurred at a significance level of p <0.05.
4.4 Results
4.4.1 Collagen Production
The average collagen production in static group was found to be 40.91± 4.23 (no
flow, no flexure), 93.2912.6 (flow-alone), 69.752.68 (cyclic flexure-alone), 207.38±36.61
(flex-flow) µg/g wet weight. (Fig. 2). Collagen content of the flex-flow group was
found to be significantly higher (p<0.05) compared to the other three groups. There
was no significant difference found among static, flow only and flex only groups. This
observation is in well agreement with previous findings [10]. For comparison, the
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collagen content of porcine aortic valve leaflets were evaluated (n = 3 leaflets) and
found to be 2141.17±491.56 µmg/g wet weight.
Figure 4.2: Collagen content in specimens derived from each group investigated.
The Flex-Flow group produced significantly (p <0.05) higher collagen compared to
all other groups
4.4.2 Gene expression
The highest level of expression for both FZD2 and YARS markers, for cardiovascular
SMC (when MLC1f is not expressed) and valvular-EC related genes respectively,
were observed in RNA extracted from the flex-flow group in which the samples were
exposed to combined cyclic flexure (1 Hz) and flow (850 ml/min) conditions in the
bioreactor (Fig. 3); note that MLC1f was only significantly expressed in the no flow
control group (P <0.05) The Klf2a, transcription factor, critical for valvulogenesis
in valve development was also expressed significantly (p <0.05) in the flex-flow case
in comparison to the other groups investigated (no flow control, flow-alone, cyclic
flexure-alone).
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Figure 4.3: Gene expression of BMSC-derived engineered valvular tissues. The four
groups investigated were: Static Controls, Flow (850 ml/min), Flex (1 Hz) and
Flex-Flow (Simultaneous application of 850 ml/min flow rate and 1Hz frequency
for cyclic bending of specimens). A flow rate of 850ml/min for cell culture media
circulating through the bioreactor conditioning chambers permitted physiologically-
relevant 4 fluid-induced mean shear stresses of 2.91 dyne/cm2 and 4.73 dynes/cm2
on the inner and outer specimen walls respectively.
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Immunostaining
It was found that only in the flex-flow group alone, α-SMA was significantly ex-
pressed in the intermediate core layer compared to surfaces of the valve leaflets
(Fig. 5). On the other hand, yet again only in the flex-flow group, the endothelial
marker protein CD31 was abundant in the surface layers (both the top and bot-
tom) compared to the intermediate core region of the specimens (Fig. 5). All other
groups produced either no expression (Static, Flexure only) or random distribution
(Flow only) of CD31 and α-SMA.
Figure 4.4: Immunofluorescence staining of porcine heart valve shows non-specific
binding. Only secondary antibody, no primary antibody, PBS was used as blocking
buffer.
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Figure 4.5: Immunofluorescence staining of α-SMA protein on both surface layers
(∼90m thickness on each side), middle core (interstitial tissue) regions (∼400 m
thickness) of the valve; 1st row: Static Controls; 2nd row: Flex; 3rd row: Flow;
4th row: Flex-Flow conditioning; 5th row: porcine heart valve as Positive control.
Among the experimental groups, α-SMA-expressing cells were found to be predom-
inant within the interstitial region (middle layer) of the engineered tissues in solely
the Flex-Flow group(continue to next page)
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Flex-Flow
PHV (+ve control)
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Figure 4.6: Immunofluorescence staining of α-SMA protein on both surface lay-
ers (∼90µm thickness on each side), middle core (interstitial tissue) regions (∼400
µmm thickness) of the valve; 1st row: Static Controls; 2nd row: Flex; 3rd row:
Flow; 4th row: Flex-Flow conditioning; 5th row: porcine heart valve as Positive
control. Among the experimental groups, α-SMA-expressing cells were found to be
predominant within the interstitial region (middle layer) of the engineered tissues
in solely the Flex-Flow group(continued from previous page)
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Figure 4.7: α-SMA expression in static control, flex only, flow only, flex-flow and
PHV (+ve control) in three different layers, such as: top, mid core and bottom of
the tissue sample.
Computational Results
The fluid-induced, time averaged shear stress magnitudes (TSSM) were plotted
on the inner and outer surfaces for all the simulation cases (Fig.4.8). The inner wall
TSSM values were 0 dyne/cm2, 1.98 ± 0.37 dyne/cm2, 0.1 ± 0.005 dyne/cm2, and
2.91 ± 0.11 dyne/cm2 for cases of static control, steady flow-alone, cyclic flexure-
alone and flex-flow. The outer wall TSSM values were 0 dyne/cm2, 2.43 ± 0.06
dyne/cm2, 0.1 ± 0.003 dyne/cm2, and 4.73 ± 0.09 dyne/cm2 for cases of control,
steady flow-alone, cyclic flexure-alone and flex-flow.
The OSI distribution was found to be much higher when exposed to cyclic
flexure-alone, relative to flex-flow conditions. The area averaged OSI on the speci-
mens inner walls (n=3) was 0.433±0.015 and 0.117± 0.003 for cyclic flexure-alone
and flex-flow cases, respectively, while the corresponding values for the outer wall
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Figure 4.8: Immunofluorescence staining of CD31, an EC marker, on both sur-
face layers (∼90mm thickness on each side), middle core sections (∼400 mm thick-
ness) of the valve tissue; 1st row: Static Controls; 2nd row: Flex; 3rd row: Flow;
4th row: Flex-Flow conditioning; 5th row: porcine heart valve as Positive con-
trol. Among the experimental groups, CD31-expressing cells were visible within the
superficial layers (top and bottom layers) of the engineered tissues, in solely the
flex-flow group.(continue to next page)
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Figure 4.9: Immunofluorescence staining of CD31, an EC marker, on both sur-
face layers (∼90mm thickness on each side), middle core sections (∼400 mm thick-
ness) of the valve tissue; 1st row: Static Controls; 2nd row: Flex; 3rd row: Flow;
4th row: Flex-Flow conditioning; 5th row: porcine heart valve as Positive con-
trol. Among the experimental groups, CD31-expressing cells were visible within the
superficial layers (top and bottom layers) of the engineered tissues, in solely the
flex-flow group.(continued from previous page)
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Figure 4.10: CD31 expression in static control, flex only, flow only, flex-flow and
PHV (+ve control) in three different layers, such as: top, mid core and bottom of
the tissue sample.
(n=3) were found to be 0.313± 0.011 and 0.094± 0.10. . The area averaged OSI- |{~τ |
metric was determined to quantify the extent of coupled shear stress magnitude and
temporal oscillations in the experiments performed. Over the specimen area (sam-
ple size n = 3/group), the area averaged OSI- |{~τ | for the inner walls were 0.1±
0.05 dyne/cm2 (cyclic flexure-alone) and 0.41± 0.11 dyne/cm2 (flex-flow), while for
the outer walls, it was 0.16 ± 0.03 dyne/cm2 (cyclic flexure-alone) and 0.270.16
dyne/cm2 (flex-flow) (Fig. 4.9).Note that OSI- |{~τ | = 0 in the event that flow is
temporally unidirectional or if fluid-induced shear stresses are negligible, which was
the case in the steady flow-alone and no flow, respectively.
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Flow direction Time averaged shear stress (Dynes/cm2)
0         4         8
Outer wall
Inner wall
Inner wall Outer wall
Flex-flow
Steady flow-alone
Static Control
Cyclic flexure-alone
Figure 4.11: Fluid-induced, time-averaged shear stresses over one cycle on specimen
inner and outer walls for the following four cases: i) Static Controls, ii) Flow, iii)
Flexure iv) Flex-Flow states. In comparing the two dynamic cases (iii) versus (iv),
the flex-flow state displayed much higher shear stress values.
Flow direction
→
− τosi
0         1          2
→
− τosi Dynes/cm2
Flex-flow
Inner wall Outer wall
Cyclic flexure-alone Outer wall
Inner wall
Figure 4.12: OSI-scaled shear stress magnitude (OSI-τ) on the inner and outer
specimen surface for the dynamic Flex and Flex-Flow cases.
81
4.5 Discussion
Functional replacement of anomalous heart valves, particularly in the case of
pediatric critical valve disease, is in dire need of suitable treatment approaches;
the primary limitation is that currently available replacement devices do not offer
provision for somatic growth. For this reason, the notion of autologous and living bi-
ological heart valve substitutes is very appealing. Several studies have demonstrated
that the process of developing robust engineered valvular tissues necessitates a dy-
namic culture process, wherein mechanical stresses, such as flow, flexure and stretch,
are imparted onto the growing constructs [10], [136], [69], [127], [74], [143]. These
stress states are particularly relevant because valve leaflets experience highly varied
and leaflet side-dependent, fluid-induced shear stress distributions, as well as local-
ized cyclic tissue stretching and flexure during the cardiac cycle. In the aortic valve
for example, the ventricular-side of the leaflet experiences significantly higher fluid-
induced shear stresses compared to the arterial-side. Some in vitro investigations
have been able to recapitulate important features of this hemodynamic environment
using bioreactors to grow de novo valvular tissues [74], [105], [97]. However, the spe-
cific effects of in vitro mechanical conditioning on cell distribution and phenotype
within the construct remain unclear. These attributes could support the integration
of engineered to native tissues, and thus could play a critical role in guiding subse-
quent valve remodeling events in vivo. Moreover, the importance of maintaining a
physiological range of conditioning parameters (e.g. fluid-induced shear stress) has
also not been sufficiently addressed [144], [132]. . On the other hand, the utility
of stem cells, such as BMSCs, has been explored in several heart valve tissue engi-
neering approaches to date, which have demonstrated robust tissue growth under
mechanical-stimulated environments [10], [69], [74]. Thus, in an attempt to iden-
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tify the effects of valve-relevant stress environments on stem cell phenotype, as well
as the implications of physiological scales of mechanical conditioning, here we sub-
jected BMSC-seeded scaffolds to individual and combined modes of fluid shear and
flexural stress states, which are both highly relevant to valvular tissues.
We found a significant (p<0.05) increase in the BMSC-derived collagen
content in the flex-flow group relative to the other groups, whereas no significant
differences were found among the Static Control, Flex and Flow groups (Fig. 2). Our
observation was consistent with previous findings (Engelmayr et al.) [10] who con-
ducted Flex-Flow studies under sub-physiological levels of shear stress (average wall
shear stress=1.15dynes/cm2) [?]combined with physiological levels of cyclic flexure
(1Hz, which corresponds to a heart rate of 60 beats/minute). However, we attempted
to recapitulate the regionally varying and side-specific nature of fluid-induced, shear
stress distribution of native aortic valves on our engineered tissue specimens. Indeed,
previous work [74] has demonstrated that the inner and outer walls of our specimens
are analogous to the aortic and ventricular-side of the leaflets. Here, under flex-flow
states, the TSSM on the outer wall was 4.73 dynes/cm2, while along the inner wall,
the shear stress was found to be 2.91 dyne/cm2. The ventricular side of the native
human aortic valve is exposed to a TSSM in the order of ∼ 3.87 dynes/cm2 [110] and
thus, the shear stresses determined for the flex-flow specimens in this study are phys-
iologically relevant. In comparing our studies to those conducted at sub-physiologic
shear stress levels and thus, the shear stresses determined for the flex-flow specimens
in this study are physiologically relevant. In comparing our studies to those con-
ducted at sub-physiologic shear stress levels [10], [?], we found an additional increase
in collagen production by 70%, i.e., when the specimen shear stress magnitudes and
distribution were regionally similar to native aortic valve leaflets. We note that an
earlier study22 demonstrated the importance of physiological scales of conditioning
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by way of mimicking arterial pressure conditions in vitro, which ultimately resulted
in ∼ 35% increase in collagen content compared to sub-physiological flow environ-
ments. We speculate that the differences were more pronounced in our case as a
direct result of cell regulatory mechanisms that are known to be initiated by fluid-
induced shear stresses [145], [118], [146], [147], [148], [149]and which we believe to
also be applicable to differentiating BMSCs.
We found that flex-flow conditioning significantly augmented (p ¡ 0.05) the
klf2a gene compared to all other groups (Fig.4.3). In native valve development, the
absence of klf2a leads to substantial valve malformations and is directly modulated
by oscillatory fluid-induced shear stresses [96]. Interestingly, we were able to demon-
strate that the upregulated expression of Klf2a by stem cells rather than endogenous
valvular cells, specifically BMSCs, is also possible when subjected to flex-flow condi-
tions. Our previous work showed that OSS are enhanced under flex-flow conditions
and hence are likely to have elicited cellular upregulation of Klf2a.
In investigation of the valvular endothelial cell marker YARS, we found
a significantly higher expression (p <0.05) once again, in only the flex-flow group,
compared to the other groups (Fig. 4.3). This result demonstrates the mediation
of mesenchymal to endothelial differentiations pathways, primarily via physiological
levels of fluid-induced shear stresses, which can be further enhanced by oscillations
in the flow field.
When making collective comparisons of Klf2a and YARS markers observed
in the flex-flow group relative to corresponding native valve gene expression, we
found, not surprisingly, that native valve expression was higher, in the order of 49%
and 70%respectively. The marked lower density of BMSCs in time-limited, in vitro
culture environments is likely to have exhibited truncated gene expression levels
compared to gene expression of cells obtained from native valvular tissues. The
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broader argument that needs to be considered however, is that the promotion of the
valvular phenotype in vitro, even if it is small, may be critical in the integration
of the engineered to native valvular tissues after implantation. From a phenotypic
viewpoint, the recognition of the engineered construct by its surrounding in vivo
cellular environment is likely to be critical in paracrine cell signaling events, which
will serve to ensure guided remodeling of the TEHV and minimize the risk of tissue
overgrowth and uncontrolled pannus. Previous studies have already demonstrated
the importance of recapitulating the native tri-layer tissue structure in TEHVs in
support of robust functionality [31], [9]. Similarly, we speculate that the phenotypic
state of BMSC-derived engineered constructs is equally important prior to implan-
tation, which we show here to be directed toward the valvular lineage under flex-flow
mechanical conditioning. We note that in addition to the strong expression of the
YARS gene, indicative of the valve endothelial cell phenotype, that the specimens in
the flex-flow group exhibited robust expression of FZD2 and an absence of MLC1F,
suggesting a smooth muscle-like phenotype unique only to the heart valves and the
pericardium [150], [140].Thus, we interpret that flex-flow mechanical conditioning
during in vitro culture of engineered tissues supports BMSC differentiation in a het-
erogeneous manner, i.e., by promoting both the valvular endothelial and interstitial
cell phenotypes. This finding corroborates our previous computational predictions
that associated the simultaneous presence of both OSS and the critical magnitude
of shear stress during flex-flow states to synergistically increase collagen content
in the engineered [97],which appears to also enhance, as evidenced here, the valve
phenotype.
Previous investigations have examined the through-thickness distribution
of cells and phenotype in TEHVs [10], [90]. Consistent with flex-flow studies that
employed a sub-physiologic range of shear stress conditioning [10] we observed that
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endothelial cellular expression was expressed primarily on the surfaces and was neg-
ligible in the interstitial layers (Fig.4.5).We interpret that BMSC to endothelial cell
differentiation and intra-scaffold BMSC migration patterns are enhanced under flow
states and is not strongly flow magnitude-dependent. Indeed, we previously visu-
alized and monitored the increase in cell scaffold migratory patterns via magnetic
resonance imaging, which was found to be augmented under steady flow-alone con-
ditions compared to no flow controls [151].On the other hand, the link between the
mechanical environments and α-SMA expressing cells within the de novo valvular
tissues is not as straightforward. Engelmayr et al [10] showed robust expression of
α-SMA-expressing BMSCs preferentially distributed on the surfaces of engineered
heart valve tissues, after being subjected to Flex-Flow states with sub-physiological
magnitudes of fluid-induced shear stresses. Meanwhile, Hoestrup and colleagues [90]
described a consistent distribution of α-SMA-expressing BMSCs throughout tri-
leaflet engineered valvular constructs subjected to physiological pressure ranges (30
to 75 mmHg) in a bioreactor; cell density was in addition the greatest on the surface
of the TEHVs, and sparse deep within the tissues.We observed that application of
heart valve, physiologically relevant fluid-induced shear stresses (TSSM for, inner
wall: 2.91 dyne/cm2 and outer wall: 4.73 dyne/cm2) served to promote cellularity,
particularly, α-SMA-expressing BMSCs (Fig. 5). While this occurred under both
flow-alone and flex-flow conditions, it was only in the latter group where α-SMA-
expressing cells were predominant within the interstitial regions of the engineered
tissues and were found to be sparse on the superficial layers. On the other hand, as
described earlier, CD31-expressing cells indicative of an endothelial phenotype were
distributed preferentially on the surfaces of the engineered tissues specimens in only
the flex-flow group. Even though the extent of both α-SMA and CD31 immunos-
taining was less pronounced than native valves, as was also evidenced for the valve-
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relevant markers in the gene expression outcomes, it is clear that physiological scales
of flex-flow conditioning promote heterogeneous cell distribution in a manner that
mimics native valve cellular distribution. We interpret the ability to achieve hetero-
geneous, valve-relevant, BMSC distribution and differentiation in an in vitro setting
to play a critical role in continued tissue remodeling after implantation, including
accelerated replication of the native tri-layered valves structure. Such a structure
has only been observed in Ovine studies after several weeks (16 32 weeks) [9]fol-
lowing TEHV implantation, and has been limited to solely the replacement of the
pulmonary valve rather than the more demanding aortic or mitral positions. Thus,
in specific cases of heart valve diseases, such as for example, in the treatment of
critical congenital aortic valve stenosis in infants [152], [153], [154], [155], [156], ac-
celerated tissue remodeling may be especially important in order to keep pace with
somatic growth.
In summary, physiologically relevant flex-flow states serve to promote cell
distribution and phenotype in in vitro grown, BMSC-derived, engineered heart valve
tissues.We were able to demonstrate for the first time that the concomitance of
OSS and critical levels of shear stress enabled the robust expression of key valvular
genes, notably Klf2a and YARs. Note that flex states-alone induce OSS but have
negligible shear stress magnitudes and were found to not augment the cellularity
and phenotype within the engineered tissues; this is consistent with our previous
findings [97]in that both temporal directionality and the magnitude of shear stress
is important in eliciting BMSC responses, which we showed here can be achieved
experimentally under flex-flow states. In addition, BMSC differentiation and mi-
gration within engineered tissues led to surface-lined endothelial-marker expressing
cells and interstitium-filled, myofibroblast-marker expressing cells, thereby resem-
bling native valve cellular distribution. We conclude that the in vitro optimization
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of BMSC-derived, engineered heart valve cellular make-up and phenotype is achiev-
able through flex-flow conditions of physiological relevance. This ability to stimulate
heterogeneous valvular cellularity and phenotype is likely to be important in guid-
ing subsequent in vivo valve tissue remodeling events and hence, towards ensuring
long-term success of the TEHV in pediatric patients.
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CHAPTER 5
Conclusion,Limitation and Future study
Tissue engineering is proposed to be the next generation treatment for complex
medical conditions. Combination of stem cell therapy, regenerative medicine, 3D
printing of living organs are becoming a new generation of treatment approach and
gaining success clinically. It is not clear if one single technique or a combination of
techniques will dominate the clinical application in next decade; but it is exciting
to note that many of the deadly diseases can be probed and treatments can be
available for human welfare. In case of heart valve, it is predicted that valve disease
will increase three times in next five decades, which pose heavy burden on society,
health care and economy [61].
5.1 Conclusion
This study presents a novel approach for tissue engineering of heart valve utiliz-
ing bone marrow stem cells, polymer scaffolds in vitro. Specifically a guided strategy
for stem cell differentiation into valvular cell lineages with an optimal biomechanical
and/or biochemical signal were developed. In this study, we focused out investiga-
tion on gene expression and protein distribution while being subjected to physio-
logically relevant mechanical conditioning. The physiological parameters were: 4.73
dynes/cm2 of mean fluid-induced shear stress and 1 Hz of cyclic flexure. In the 1st
chapter of this dissertation, the motivation behind this study is presented. Current
treatments for HV diseases, treatment options and related challenges are mentioned.
The unanimous need for an alternate approach was discussed; ultimately, to date,
however obtaining a functional TEHV remains a challenge. The following hypothesis
was proposed in vitro oscillatory shear stress via flex-flow states regulates human
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bone marrow mesenchymal stem cells to differentiate to heart valve phenotypes.
Three specific aims were defined and investigated; I) Apply oscillatory shear stress
(OSS) to a two dimensional (2D) bone marrow mesenchymal stem cell (BMSCs)
mono-layer to observe the changes in cell entities, such as f- actin and vinculin.
F-actin is a cytoskeletal protein, vinculin is a focal adhesion protein and both are
known to respond to shear stresses. After a duration of 8 days OSS application, cells
will be evaluated for endothelial cell expression by immunofluorescence technique to
detect CD31 which is a marker for EC and expressed on EC surface. This inves-
tigation demonstrated that OSS can differentiate BMSCs to endothelial cell (EC).
II) Apply physiologically relevant heart valve shear stress conditions such as flow
and/or flexure to three dimensional (3D) BMSC-seeded polymer scaffolds to study
the effects of mechanical regulation on tissue regeneration and associated ECM com-
ponents such as collagen production. III) Apply heart valve relevant shear stress
conditions as in specific aim 2 to 3D BMSC-seeded scaffold to investigate gene and
protein expression in engineered tissue.
In the 2nd chapter a critical review of previous studies was presented.
Reviews were discussed to understand different viewpoints and proposed methods
and developments in a chronological manner. Brief descriptions of current available
treatments in the form of mechanical and bioprosthetic heart valves were tabulated.
The requirement of TEHV was discussed. Currents status, challenges and future
objectives were mentioned in an extensive manner. The possibilities of a new gen-
eration treatments were detailed. It is very clear that with the availability of stem
cell therapy, synthetic and natural scaffolds and advanced surgical expertise, TEHV
is a potential treatment of the future; however caution should be made selecting
cell source, scaffold material and implantation techniques. There has been tremen-
dous efforts and improvements made to obtain a suitable functional TEHV; it will
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still take extensive research and developments to accomplish the goal. Various ex-
pertise in the field of science, engineering and medicine need to be combined to
identify important elements in heart valve developmental biology, chemical require-
ments, engineered design and ease of implantation to eventually optimize construct
functionality.
In the 3rd chapter a study of biochemical and mechanical components
were presented. In this study a group of bone marrow mesenchymal stem cells were
treated with a low dose nicotine, a chemical component known to induce endothe-
lial differentiation; whereas other group was exposed to oscillatory shear stress, a
mechanical stimulant to induce endothelial cell differentiation. The objective of
the study was to evaluate if BMSCs were responsive to mechanical stimulation and
whether OSS induce endothelial differentiation. This study proposed that, while
Nicotine may stimulate an increase in the differentiation of BMSCs to endothelial
cells, OSS may play a greater role in cellular distribution, and the eventual creation
of a tissue engineered heart valves (TEHV) endothelium [157].
In 4th chapter, experimental details of a 3D in vitro study for heart valve
tissue engineering was discussed. Briefly, BMSCs seeded polymer constructs were
recruited in physiological flow, flexure conditions. A custom made FSF bioreac-
tor was deployed to produce physiological flow of 850ml/min, flexure of 1Hz and
a combination of both flow and flexure on the tissue samples. After 22 days of
conditioning neo tissue was formed and evaluated for heart valve characteristics
such as gene expression, protein expression, collagen production and tissue layer
formation. Significant collagen was produced in flex-flow group, which is well in
agreement with previous pioneer study performed by Engelmayr group [10]. Pre-
vious studies have presented encouraging results in direct implantation of natural
or synthetic scaffolds with or without cell seeded constructs in vivo; however, these
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valve constructs failed within few years of implant [20], [21]. Compromised mechan-
ical properties, calcification or fibrosis were the cause of failure. In order to create
a long term viable construct, biological properties such as gene regulation, protein
expression during various stages of valve implant should be addressed. Therefore,
our study focused on the effects of various mechanical signaling on tissue regener-
ation and gene and protein expression. Some promising results obtained from the
experiments were presented. It is concluded that an appreciable amount of shear
stress magnitude combined with oscillatory shear stress in the physiological range
regulates heart valve relevant gene expression and protein organization. Specifically,
the mechanical combination of 4.73 dynes/cm2 steady flow with 1 Hz cyclic flexure,
both within physiological magnitudes promoted heterogeneous BMSC differentia-
tion to valve endothelial and myofibroblast phenotypes. In addition differentiated
cells were preferentially distributed spatially, with endothelial cells on the surface
while α-SMA positive expressing cells were found predominantly deep within the
engineered valvular tissues.
5.2 Limitations
This study was focused primarily on evaluating physiologic mechanical condi-
tioning parameters for generating valve tissue with characteristic expressions of valve
relevant phenotypes. Even though we found some exciting results that provided
insight into valvulogenesis of BMSCs in physiological flexure and flow condition,
however this study has some limitations.
1) The total sample size for the experiment is 48. Each group has 12 samples.
Four diff t outcomes, such as collagen assay to measure ECM production (2), QRT
PCR to quantify gene expression [39], [96], [137], immunostaining to locate protein
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distribution [29], [36] and histology to observe the valve tri layer ECM structure [9]
were evaluated. Each outcome has a sample size of 3, which limit the power analysis
of the experiment. A one way analysis of variance (one way ANOVA) test was
performed to find out significant difference in the collagen production and gene
expression. A Tukeys post hoc analysis suggests flex-flow group has significant
collagen production and two critical valve relevant gene such as klf2a and YARS
expression compared to all other groups. In order to get more conclusive results;
greater sample size should be considered.
Figure 5.1: A one way analysis of variance (one way ANOVA) test showing signifi-
cant difference in the collagen production
2) This experiment used a polyglycolic acid (PGA) and poly L lactic acid
(PLLA) equal ratio matrix as the base to regenerate the valve tissue. Even if
this polymer is widely used in tissue engineering experiments, it is not suitable for
valve regeneration. The valve mechanical properties are not compatible with this
polymers strength and flexibility. Therefore, a suitable biodegradable scaffold should
be identified. In order to mimic the physiological condition, the engineered valve
tissue should ideally be oriented perpendicular to the flow direction. In this study
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Figure 5.2: Result of Anova analysis
Figure 5.3: Analysis of variance
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all our samples were positioned parallel to the flow direction, which was intrinsic to
bioreactor design.
3) Most of the valve regeneration study fails after few years of implantation due
to compromised biological or mechanical properties. So animal model for in vivo
studies should be performed as the next step in this research, wherein the engineered
tissues grown in this study be investigated for valve repair or replacement purposes.
5.3 Future Study
More in vitro study is required to obtain statistical significance of the pre-
sented results. In vivo animal study in Ovine or Sheep model should be performed.
Currently, we have obtained some natural tissue matrix derived from porcine small
intestine submucosa (SIS), which shows promising results in vascular graft, peri-
cardium repair; however, valve application of this material is not yet evaluated.
Therefore, a similar in vitro study using SIS should be designed to evaluate the
gene expression and protein distribution in detail.
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